[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 279
1. Elder JB, Atkinson R, Zee CS, Chen TC: Primary intraosseous meningioma. Neurosurg Focus; 2007;23(4):E13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intraosseous meningioma.
  • Primary intraosseous meningiomas are a subtype of primary extradural meningiomas and constitute fewer than 2% of meningiomas overall, but they represent approximately two thirds of all extradural meningiomas.
  • These types of meningiomas originate within the bones of the skull and thus can have a clinical presentation and radiographic differential diagnosis that is different from those for intradural meningiomas.
  • Primary intraosseous meningiomas are classified based on their location and histopathological characteristics.
  • Treatment primarily involves resection with wide margins if possible.
  • Very little literature exists regarding the use of adjuvant therapies such as radiation and chemotherapy for these tumors.
  • In fact, the literature regarding primary intra-osseous meningiomas consists mostly of clinical case reports and case series.
  • [MeSH-major] Meningioma / diagnosis. Meningioma / therapy. Skull Neoplasms / diagnosis. Skull Neoplasms / therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961037.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


2. Yonekawa Y: [Operative neurosurgery: personal view and historical backgrounds. (5) Meningioma]. No Shinkei Geka; 2009 Jan;37(1):71-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative neurosurgery: personal view and historical backgrounds. (5) Meningioma].
  • The author reports his experience of 410 surgeries of meningiomas on 365 cases during the last 13.5 years, including 51 surgeries on recurrent meningiomas and 8 surgeries with the change of initial approach on the same meningiomas.
  • In the surgical management of meningiomas, following comments are to be emphasized: Appropriate approach and interruption of blood supply are of cardinal importance in surgical management of meningiomas.
  • For the latter purpose, preoperative embolization of feeding arteries is recommended especially in deep seated and large meningiomas more than 3 cm in diameter for carrying out their surgical extirpation fast and radically.
  • Olfactory groove meningiomas, planum sphenoidal meningiomas, tuberculum sellae meningiomas and sphenoid ridge meningiomas are managed with pterional approach.
  • The latter two meningiomas may necessitate selective extradural anterior clinoidectomy SEAC.
  • For the management of large midline meningiomas, combination with interhemispheric approach is necessary to manage pial supply appropriately for the preservation of circulation of the anterior cerebral artery ACA.
  • Extension of the former two meningiomas to the other side can be managed with falcal incision and/or drilling out of the crista galli without performing a bifrontal approach.
  • Reduction of exophthalmos due to sphenoid ridge meningiomas infiltrating Periorbita and extraocular muscles is hardly to be expected even after subtotal removal and extensive decompression of the orbita at the superior and lateral walls in combination with SEAC.
  • Accidental compromise of the lenticulostriate arteries arising from M1 portion embraced by tumor nodules should be managed with oxycellulose and fibrin glue at first without their bipolar coagulation, as resulting infarction in the territory causes persistent hemiparesis.
  • Meningiomas in the cavernous sinus should be observed as long as possible in case of no growth, as they remain the same in their size and extension mostly for a long time.
  • Appropriate approaches for meningiomas arising from the incisura tentorii would be either the amygdalohippocampectomy AHE approach namely transSylvian transsulcus circularis approach for their anterior localization or the supracerebellar transtentorial SCTT approach for the posterior localization in the sitting position.
  • In the latter following structures are to be preserved with great care: A. parietooccipitalis, trochlear nerve, Vena Rosenthal and the superior cerebellar artery which could have considerable supply to the tumor.
  • Meningiomas of the falcotentorial junction are managed also with this approach but may necessitate combination of the suboccipital transtentorial approach large upper clivus meningiomas can be removed more effectively by paramedian or lateral suboccipital craniotomy via SCTT approach in the sitting position rather than the subtemporal transpetrosal approach.
  • Special mention is made to transvertebralis (dural) ring approach TVRA for the foramen magnum or lower clivus meningiomas, in which the vertebral artery can be mobilized without performing more extensive far lateral approach.
  • Difficulties of management of recurrent parasagittal meningiomas with the location corresponding to the gyrus paracentralis plus supplementary motor area are to be emphasized.
  • Difficulties of management of recurrent meningiomas represented by atypical or anaplastic meningiomas WHO grade II or III which can not be managed only by surgical removal is discussed by presenting some example cases.
  • Biological activity of meningiomas in different location can be quite different in multiple recurrent meningiomas.
  • Meningiomas intractable to irradiation and/or chemotherapy are another challenging topic, being beyond the scope of this paper.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Neurosurgical Procedures / methods
  • [MeSH-minor] Aged. Diagnostic Imaging. Embolization, Therapeutic. Female. Humans. Male. Middle Aged. Preoperative Care

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175037.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 39
  •  go-up   go-down


3. Andersen C: [Intracranial meningioma. New knowledge]. Ugeskr Laeger; 2001 May 7;163(19):2618-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial meningioma. New knowledge].
  • [Transliterated title] Meningeoma intracraniale. Ny viden.
  • Meningiomas are classified according to WHO (1993), and include eleven subtypes of benign meningiomas, two semi-malignant and one anaplastic.
  • In most cases meningiomas exhibit modifications or deletions in chromosome 22.
  • Increasing knowledge of the natural history concerning growth rate and the treatment of incidental meningiomas is accumulating.
  • Meningiomas formerly classified as surgically inaccessible are now often operable due to a continuing refinement of the surgical techniques and the study of possible new routes of intracranial tumour removal.
  • [MeSH-major] Brain Neoplasms. Meningioma
  • [MeSH-minor] Chromosome Deletion. Chromosomes, Human, Pair 22. Combined Modality Therapy. Humans. Receptors, Cell Surface / drug effects. Receptors, Cell Surface / metabolism. Risk Factors

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11360354.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptors, Cell Surface
  • [Number-of-references] 38
  •  go-up   go-down


Advertisement
4. Gallerani M, Mari E, Boari B, Carletti R, Marra A, Cavallo M: Pancytopenia associated with levetiracetam treatment. Clin Drug Investig; 2009;29(11):747-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancytopenia associated with levetiracetam treatment.
  • Levetiracetam is a pyrrolidine derivate that is approved for the treatment of seizures.
  • It has a favourable pharmacokinetic profile, no clearly established pharmacological interactions, good tolerability and offers the possibility of rapid treatment.
  • We describe a case of pancytopenia and multiple infections observed in the context of levetiracetam treatment.
  • A 65-year-old woman who underwent surgical removal of a meningioma developed progressive pancytopenia complicated by pneumonia and multiple liver abscesses after starting levetiracetam therapy.
  • Bone marrow aspiration and biopsy confirmed the diagnosis.

  • Hazardous Substances Data Bank. PIRACETAM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epilepsia. 2004 Jul;45(7):877-8 [15230717.001]
  • [Cites] Acta Neurol Scand. 2006 Sep;114(3):169-76 [16911344.001]
  • [Cites] Epilepsy Res. 2008 Jul;80(1):91-2 [18424076.001]
  • [Cites] Actas Esp Psiquiatr. 2004 Sep-Oct;32(5):327-8 [15529219.001]
  • [Cites] Epilepsia. 2002 May;43(5):518-24 [12027913.001]
  • [Cites] Acta Neurol Belg. 2007 Dec;107(4):97-102 [18416281.001]
  • [Cites] Clin Pharmacol Ther. 1981 Aug;30(2):239-45 [7249508.001]
  • [Cites] Expert Opin Drug Saf. 2007 May;6(3):241-50 [17480174.001]
  • [Cites] CNS Drug Rev. 2007 Spring;13(1):57-78 [17461890.001]
  • [Cites] Ann Pharmacother. 2009 May;43(5):985 [19417118.001]
  • (PMID = 19813778.001).
  • [ISSN] 1173-2563
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anticonvulsants; 230447L0GL / etiracetam; ZH516LNZ10 / Piracetam
  •  go-up   go-down


5. van den Bent MJ, Stupp R, Brandes AA, Lacombe D: Current and future trials of the EORTC brain tumor group. Onkologie; 2004 Jun;27(3):246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current and future trials of the EORTC brain tumor group.
  • The EORTC Brain Tumor Group (BTG) is dedicated to clinical research of neoplasms of the brain.
  • In the past years the BTG has carried out phase II and phase III trials on glial tumors, brain metastases and primary CNS lymphomas.
  • Future studies will investigate novel drugs in combination with chemo-radiotherapy in glioblastoma multiforme, radiotherapy in meningioma, and chemotherapy in medulloblastoma.
  • The wide recognition of the importance of translational research for clinical trials and in particular with targeted therapies implies that this type of research will become a mandatory element in many of our future trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Clinical Trials as Topic / methods. Clinical Trials as Topic / trends
  • [MeSH-minor] Combined Modality Therapy. European Union. Glioma / drug therapy. Glioma / radiotherapy. Humans


6. Hemminki K, Lenner P, Sundquist J, Bermejo JL: Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol; 2008 Apr 10;26(11):1850-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis.
  • PURPOSE: Quantitative data on subsequent cancers after primary cancers provide information on treatment-related risks on second cancers, with implications for therapeutic adverse effects and human susceptibility in general.
  • Quantitative data on solid tumors are limited.
  • We focus on survivors of non-Hodgkin's lymphoma (NHL) because the disease is diagnosed at a wide range of ages and treated uniformly primarily with chemotherapy.
  • RESULTS: The SIR for solid tumors after NHL was 1.65 (2,290 patients) and that for lymphohematopoietic neoplasms was 5.36 (369 patients).
  • Among the 25 most common solid tumors, the SIRs were increased for all but nine sites; the highest SIR (40.8) was observed for spinal meningioma.
  • The SIRs for solid tumors declined in an age-dependent manner from 4.52 in diagnostic age younger than 20 years to 1.12 in diagnostic age 70+ years.
  • In the most common patient groups, the SIRs for solid tumors increased up to 30 years after NHL diagnosis.
  • Because of the high incidence of solid tumors in these age groups, they contributed the largest numbers of therapy-related cases.
  • CONCLUSION: These data indicate that age at treatment determines both the magnitude of the initial relative risk and the time-dependent modulation of the response.
  • Therapy-related damage persists at least 30 years and its toll of solid tumors is largest 21 to 30 years after diagnosis.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age of Onset. Aged. Aging. Child. Child, Preschool. Comorbidity. Female. Follow-Up Studies. Humans. Incidence. Infant. Infant, Newborn. Male. Meningioma / diagnosis. Meningioma / epidemiology. Middle Aged. Registries. Risk Assessment. Sex Distribution. Spinal Neoplasms / diagnosis. Spinal Neoplasms / epidemiology. Sweden / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347006.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol; 2006 Jul;78(3):271-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent meningioma.
  • BACKGROUND: A prospective Phase II study of irinotecan (CPT-11) in adult patients with recurrent surgery and radiotherapy-refractory WHO Grade I meningioma.
  • METHODS: Sixteen patients (5 men; 11 women) ages 48-70 years (median 62.5), with recurrent meningioma were treated.
  • All patients had previously been treated with surgery (complete in 4; partial in 9; biopsy in 3) and involved-field radiotherapy (median dose 54 Gy; 12 following first surgery and 4 following second surgery).
  • No patient was treated with prior chemotherapy.
  • One patient developed neutropenic fever without bacteriologic confirmation.
  • No treatment-related deaths occurred.
  • No patient demonstrated a neuroradiographic complete or partial response (PR), 13 patients (81%) demonstrated stable disease but disease progressed after 2 cycles of CPT-11, and 3 patients (19%) had progressive disease (PD) following a single cycle of CPT-11.
  • Time to tumor progression ranged from 2.5 to 5.0 months (median 5.0 months).
  • Using CPT-11 in this moderately toxic dose schedule failed to demonstrate efficacy in this cohort of adult patients with recurrent surgery and radiotherapy-refractory meningioma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Meningioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Aged. Agranulocytosis / chemically induced. Anticonvulsants / therapeutic use. Diarrhea / chemically induced. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Leukopenia / chemically induced. Male. Middle Aged. Treatment Failure

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1994 Nov;81(5):666-75 [7931612.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] J Neurooncol. 1990 Feb;8(1):61-5 [2319292.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):42-9 [10413154.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurosurg. 1997 May;86(5):845-52 [9126901.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):269-72 [8858533.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):545-7 [2398385.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):65-72 [12134934.001]
  • [Cites] Neurology. 1997 May;48(5):1459-62 [9153494.001]
  • [Cites] Neurology. 1998 Dec;51(6):1718-20 [9855530.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Lancet. 1995 Feb 4;345(8945):331 [7837901.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):187-90 [8283254.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):552-9 [2002367.001]
  • (PMID = 16628476.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


8. Park I, Huh J, Kim JH, Lee SW, Ryu MH, Kang YK: Primary central nervous system marginal zone B-cell lymphoma of the Basal Ganglia mimicking low-grade glioma: a case report and review of the literature. Clin Lymphoma Myeloma; 2008 Oct;8(5):305-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary central nervous system (CNS) marginal zone B-cell lymphoma (MZBL) is very rare and shows an indolent disease course with potential of being cured.
  • Primary CNS MZBL is often misdiagnosed as meningioma because of its similar tumor locations and appearances on magnetic resonance imaging (MRI).
  • Surgery, radiation therapy, chemotherapy, and combinations of these are considered treatment modalities depending on the case.
  • After an MRI scan of the brain, wherein he was first diagnosed with high-grade glioma, a biopsy sample showed that he had primary CNS MZBL arising in the left basal ganglia.
  • He was treated with radiation therapy, which resulted in complete remission for 1 year and 10 months up to the date of this case report.
  • It is important to diagnose primary CNS MZBL correctly because it is curable without unnecessary invasive treatment in cases of localized disease.
  • [MeSH-major] Basal Ganglia / pathology. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / radiotherapy. Glioma / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / radiotherapy
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Humans. Male. Recovery of Function. Remission Induction

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854286.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Sorimachi T, Maruya J, Mizusawa Y, Ito Y, Takeuchi S: Glaucoma as a complication of superselective ophthalmic angiography. AJNR Am J Neuroradiol; 2003 Sep;24(8):1552-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of glaucoma that resulted as a complication of superselective ophthalmic angiography in a 67-year-old man with a recurrent olfactory groove meningioma.
  • Early treatment, including laser iridotomy, relieved the symptoms completely.
  • [MeSH-major] Contrast Media / adverse effects. Embolization, Therapeutic / adverse effects. Glaucoma, Angle-Closure / chemically induced. Ioxaglic Acid / adverse effects. Meningeal Neoplasms / blood supply. Meningeal Neoplasms / therapy. Meningioma / blood supply. Meningioma / therapy. Neoadjuvant Therapy. Ophthalmic Artery / radiography
  • [MeSH-minor] Adult. Aged. Humans. Injections, Intra-Arterial. Intraocular Pressure / drug effects. Male

  • Genetic Alliance. consumer health - Glaucoma.
  • Hazardous Substances Data Bank. Ioxaglate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13679269.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; Z40X7EI2AF / Ioxaglic Acid
  •  go-up   go-down


10. Huang B, Lei T, Liu K, Zhang L, Li L, Zhang Z, Xue D: The regulatory effects of protein kinase C on the proliferation of cultured human low-passage meningioma cells. J Tongji Med Univ; 2000;20(3):217-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The regulatory effects of protein kinase C on the proliferation of cultured human low-passage meningioma cells.
  • The potential role of the protein kinase C (PKC)-mediated signal transduction pathways in growth regulation was evaluated and the effects and the possible mechanism of PKC inhibitor on low-passage human meningioma cells in vitro investigated.
  • Freshly resected meningiomas obtained from the operation were placed into cell cultures.
  • The numbers of the cultured meningioma cells were counted to evaluate the effect of the PKC inhibitor staurosporine on proliferation of meningioma cells.
  • The basal phosphatidylinositol (PI) turnover rate and the inhibitory rate of starosporine on the proliferation of the meningioma cells were detected.
  • It was found that the proliferation of the low-passage human meningioma cells was inhibited by staurosporine in a dose-dependent manner.
  • It was suggested that PKC-mediated signal pathway is involved in the proliferation of the low-passage human meningioma cells.
  • The procedure that PKC regulated the proliferation of human meningioma cells is a complex procedure.
  • It is necessary to make more research in order to explore a non-operation therapy or an adjuvant therapy.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Protein Kinase C / physiology
  • [MeSH-minor] Cell Division / drug effects. Humans. Signal Transduction. Staurosporine / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11215053.001).
  • [ISSN] 0257-716X
  • [Journal-full-title] Journal of Tongji Medical University = Tong ji yi ke da xue xue bao
  • [ISO-abbreviation] J. Tongji Med. Univ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.13 / Protein Kinase C; H88EPA0A3N / Staurosporine
  •  go-up   go-down


11. Tews DS, Fleissner C, Tiziani B, Gaumann AK: Intrinsic expression of drug resistance-associated factors in meningiomas. Appl Immunohistochem Mol Morphol; 2001 Sep;9(3):242-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrinsic expression of drug resistance-associated factors in meningiomas.
  • Meningiomas, commonly benign tumors, rarely display aggressive behavior by recurrences and invasion.
  • In addition to surgery, irradiation is beneficial for recurrent, atypical, and malignant meningiomas.
  • The role of chemotherapy, however, remains controversial, although there is evidence that meningiomas respond well to adjuvant chemotherapy.
  • A major obstacle in chemotherapy remains drug resistance with reduced cellular drug accumulation through membrane efflux pumps, drug detoxification, and alterations in drug target specificity.
  • In 84 classic, atypical, and malignant meningiomas, the immunohistochemical expression profile of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), lung resistance-related protein (LRP), metallothionein, and topoisomerase IIalpha were studied.
  • All types of meningiomas showed constant expression of P-gp, LRP, MRP, and topoisomerase IIalpha; metallothionein was found in 67% of the tumors, especially in atypical and malignant meningiomas.
  • P-gp, LRP, and topoisomerase IIalpha were strongly expressed by normal and neoplastic vessels, which may confer to impaired penetration of therapeutic agents through the blood-brain and blood-tumor barrier.
  • Neither recurrent nor previously irradiated meningiomas revealed any significant difference to primary tumors.
  • These intrinsic drug resistances indicate that successful chemotherapy may require additional inhibition of these factors to be a promising approach in the management of meningiomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11556752.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins
  •  go-up   go-down


12. van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ: Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol; 2009 Sep;256(9):1519-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of anti-epileptic drugs in patients with gliomas and seizures.
  • Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited.
  • An observational study was carried out using a database of all patients from the neuro-oncology service during the period 2000-2005, with data on seizure characteristics, therapy with AEDs, the underlying brain tumor and its treatment.
  • A total of 140 brain tumor patients were studied of whom 23.6% had a low-grade glioma, 53.6% a high-grade glioma, and 22.8% belonged to a mixed group existing of ependymoma, meningioma, and brain metastasis.
  • Epilepsy as the presenting sign was more frequent in low-grade vs. high-grade gliomas (69.7 vs. 52%, P = 0.087), and a total of 75.8% of patients developed seizures with low-grade and of 80.0% with high-grade gliomas.
  • Patients treated with a combination of VPA and LEV showed the highest percentage of responders (81.5%), with a decline in seizure frequency of more than two categories in 55.6% and seizure freedom in 59%.
  • This indicates that adding levetiracetam may be preferable over sequential trials of AED monotherapy in treatment-resistant seizures in patients with brain tumors.
  • [MeSH-major] Anticonvulsants / therapeutic use. Brain Neoplasms / complications. Glioma / complications. Seizures / drug therapy. Seizures / etiology
  • [MeSH-minor] Adult. Carbamazepine / therapeutic use. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Piracetam / analogs & derivatives. Piracetam / therapeutic use. Time Factors. Treatment Outcome. Triazines / therapeutic use. Valproic Acid / therapeutic use


13. Kotil K, Bilge T, Olagac V: Primary intradural myxoid chondrosarcoma: a case report and review in the literature. J Neurooncol; 2005 Nov;75(2):169-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapeutic experience with primary spinal mesenchymal chondrosarcomas is also extremely limited.
  • INTERVENTION: At surgery, a mass found attached solely to pia mater, with a normal arachnoid and dura mater overlying was seen.
  • CONCLUSION: The differential diagnosis considered in the present case included meningioma, plasmacytoma, and non-neoplastic intradural spinal cord lesion.
  • We emphasize the benefit of surgical resection without radiotherapy and/or chemotherapy.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / diagnosis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Pia Mater / pathology
  • [MeSH-minor] Adult. Dura Mater / surgery. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Radiography. Time Factors. Treatment Outcome. X-Rays

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Aug;40(2):818-31 [890662.001]
  • [Cites] J Neurosurg. 1994 May;80(5):928-30 [8169637.001]
  • [Cites] Surg Neurol. 1989 Jun;31(6):470-2 [2718090.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Feb;81(2):828-34 [8636311.001]
  • [Cites] Clin Orthop Relat Res. 1982 Jun;(166):226-32 [7083677.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):420-3 [11220388.001]
  • [Cites] Clin Orthop Relat Res. 1993 Sep;(294):90-5 [8358950.001]
  • [Cites] Spine (Phila Pa 1976). 1978 Sep;3(3):202-9 [715548.001]
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):150-3 [7671456.001]
  • [Cites] Cancer. 1986 Jun 15;57(12 ):2444-53 [3697943.001]
  • (PMID = 16283441.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


14. Gupta R, Suri V, Jain A, Sharma MC, Sarkar C, Singh MM, Joshi NP, Puri T, Julka PK: Anaplastic meningioma in an adolescent: a report of a rare case and brief review of literature. Childs Nerv Syst; 2009 Feb;25(2):241-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma in an adolescent: a report of a rare case and brief review of literature.
  • OBJECTIVE: Anaplastic meningioma is an uncommon neoplasm in childhood and adolescence.
  • Due to the rarity, treatment options for anaplastic meningioma in this age group are not clearly outlined.
  • CASE: A 15-year-old boy presented with a left forehead swelling with a history of a left frontal tumor.
  • Radiological investigations revealed a dura-based tumor with a large extracranial and a smaller intracranial component.
  • Craniotomy with near-total excision of the tumor was performed.
  • Histopathological examination of the tumor showed features of an anaplastic meningioma.
  • The patient is currently receiving radiotherapy and chemotherapy.
  • However, he has developed scalp swellings while on radiotherapy.
  • CONCLUSION: Anaplastic meningioma is extremely rare in children.
  • Extensive sampling is required to recognize the meningothelial nature of the tumor and immunohistochemistry helps in making an accurate diagnosis in such cases.
  • Therapeutic interventions in such cases need to be closely monitored due to the aggressive behavior of this tumor.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Mucin-1 / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Child Neurol. 2006 Jan;21(1):31-6 [16551450.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):1-7 [15886506.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):179-82 [14758946.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Expert Rev Neurother. 2006 Oct;6(10):1447-64 [17078786.001]
  • [Cites] Childs Brain. 1980;7(1):43-56 [7428495.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] Childs Nerv Syst. 1986;2(3):160-1 [3779674.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] Neurol Med Chir (Tokyo). 1978;18(1 Pt 1):119-27 [77488.001]
  • (PMID = 18769931.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mucin-1; 0 / Vimentin
  • [Number-of-references] 11
  •  go-up   go-down


15. La Spina M, Dollo C, Giangaspero F, Bertolini P, Russo G: Intracranial mesenchymal chondrosarcoma with osteoid formation: report of a pediatric case. Childs Nerv Syst; 2003 Sep;19(9):680-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial mesenchymal chondrosarcoma with osteoid formation: report of a pediatric case.
  • CASE REPORT: We present a case of a 14-year-old girl with a 3-week history of severe progressive headache and intermittent vomiting.
  • A presumptive preoperative diagnosis of meningioma was made.
  • DISCUSSION: Clinical features, therapeutic approaches and prognosis of this rare tumour are discussed with regard to the known 30 cases in the literature.
  • [MeSH-minor] Adolescent. Drug Therapy. Female. Headache / etiology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Radiotherapy. Tomography, X-Ray Computed. Vomiting / etiology

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2000 Sep-Oct;7(5):1041-7 [10948336.001]
  • [Cites] No Shinkei Geka. 1981 Jun;9(7):843-8 [7266768.001]
  • [Cites] Med Pediatr Oncol. 2000 May;34(5):370-4 [10797365.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1327-35 [10751358.001]
  • [Cites] Br J Neurosurg. 2001 Oct;15(5):419-24 [11708546.001]
  • (PMID = 12700920.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, Stovall M, Frobisher C, Lancashire ER, Reulen RC, Hawkins MM: Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol; 2010 Dec 20;28(36):5287-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.
  • PURPOSE: CNS tumors are the most common second primary neoplasm (SPN) observed after childhood cancer in Britain, but the relationship of risk to doses of previous radiotherapy and chemotherapy is uncertain.
  • METHODS: The British Childhood Cancer Survivor Study is a national, population-based, cohort study of 17,980 individuals surviving at least 5 years after diagnosis of childhood cancer.
  • RESULTS: There were 137 meningiomas, 73 gliomas, and 37 other CNS neoplasms included in the analysis.
  • The risk of meningioma increased strongly, linearly, and independently with each of dose of radiation to meningeal tissue and dose of intrathecal methotrexate.
  • Those whose meningeal tissue received 0.01 to 9.99, 10.00 to 19.99, 20.00 to 29.99, 30.00 to 39.99 and≥40 Gy had risks that were two-fold, eight-fold, 52-fold, 568-fold, and 479-fold, respectively, the risks experienced by those whose meningeal tissue was unexposed.
  • The risk of meningioma among individuals receiving 1 to 39,40 to 69, and at least 70 mg/m2 of intrathecal methotrexate was 15-fold, 11-fold, and 36-fold, respectively, the risk experienced by those unexposed.
  • The risk of glioma/primitive neuroectodermal tumors increased linearly with dose of radiation, and those who had CNS tissue exposed to at least 40 Gy experienced a risk four-fold that experienced by those who had CNS tissue unexposed.
  • CONCLUSION: The largest-ever study, to our knowledge, of CNS tumors in survivors of childhood cancer indicates that the risk of meningioma increases rapidly with increased dose of radiation to meningeal tissue and with increased dose of intrathecal methotrexate.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21079138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010131-18; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS533866; NLM/ PMC4809645
  •  go-up   go-down


17. Güneş M, Günaldi O, Tuğcu B, Tanriverdi O, Güler AK, Cöllüoğlu B: Intracranial chondrosarcoma: a case report and review of the literature. Minim Invasive Neurosurg; 2009 Oct;52(5-6):238-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial chondrosarcoma: a case report and review of the literature.
  • INTRODUCTION: Chondrosarcoma is a rare malignant tumor originating from cartilagenous tissue.
  • Cranial computed tomography and magnetic resonance imaging showed a mass lesion including calcification areas and homogenous contrast enhancement in the right parieto-occipital region.
  • The tumor was removed totally by a microsurgical technique.
  • A classical type chondrosarcoma was confirmed histopathologically.
  • DISCUSSION: Intracranial chondrosarcoma has been first reported by Mott in 1899.
  • Primary intracranial chondrosarcomas, constitute only less than 0.16% of all brain tumors.
  • The choroid plexus, dura mater and brain parenchyma are extremely rarely invaded.
  • Meningiomas, solitary fibrous tumor, chordoma, hemangiopericytoma, metastasis and vascular malformations should be considered as differential diagnoses.
  • Radical surgical removal of the tumor is the preferred management procedure.
  • Chemotherapy and radiotherapy may by added as adjuvant therapy.
  • We present the case of a patient with an intracranial chondrosarcoma, who has treated successfully with surgical removal.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Chondrosarcoma / diagnosis. Chondrosarcoma / surgery
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Microsurgery. Neurosurgical Procedures. Prognosis. Tomography, X-Ray Computed. Treatment Outcome


18. Gupta V, Su YS, Samuelson CG, Liebes LF, Chamberlain MC, Hofman FM, Schönthal AH, Chen TC: Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg; 2007 Mar;106(3):455-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.
  • OBJECT: There is currently no effective chemotherapy for meningiomas.
  • Although most meningiomas are treated surgically, atypical or malignant meningiomas and surgically inaccessible meningiomas may not be removed completely.
  • The authors have investigated the effects of the topoisomerase I inhibitor irinotecan (CPT-11) on primary meningioma cultures and a malignant meningioma cell line in vitro and in vivo.
  • METHODS: The effects of irinotecan on cellular proliferation in primary meningioma cultures and the IOMM-Lee malignant meningioma cell line were measured by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide assay and flow cytometry.
  • Apoptosis following drug treatment was evaluated by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling and the DNA laddering assays.
  • The effects of irinotecan in vivo on a meningioma model were determined with a subcutaneous murine tumor model using the IOMM-Lee cell line.
  • Irinotecan induced a dose-dependent antiproliferative effect with subsequent apoptosis in the primary meningioma cultures (at doses up to 100 microM) as well as in the IOMM-Lee human malignant meningioma cell line (at doses up to 20 microM) irinotecan.
  • In the animal model, irinotecan treatment led to a statistically significant decrease in tumor growth that was accompanied by a decrease in Bcl-2 and survivin levels and an increase in apoptotic cell death.
  • CONCLUSIONS: Irinotecan demonstrated growth-inhibitory effects in meningiomas both in vitro and in vivo.
  • Irinotecan was much more effective against the malignant meningioma cell line than against primary meningioma cultures.
  • Therefore, this drug may have an important therapeutic role in the treatment of atypical or malignant meningiomas and should be evaluated further for this purpose.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Meningioma / drug therapy. Meningioma / pathology. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology. Subcutaneous Tissue
  • [MeSH-minor] Animals. Apoptosis / physiology. Cell Culture Techniques. Cell Line, Tumor. Disease Models, Animal. Male. Mice. Mice, Nude. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367069.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Proto-Oncogene Proteins c-bcl-2; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


19. Picquet J, Valo I, Jousset Y, Enon B: Primary pulmonary meningioma first suspected of being a lung metastasis. Ann Thorac Surg; 2005 Apr;79(4):1407-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary meningioma first suspected of being a lung metastasis.
  • Primary extracranial and extraspinal meningiomas are rare tumors.
  • We describe a primary pulmonary meningioma first suspected of being a metastasis because it presented as a solitary subpleural pulmonary nodule in a patient with breast cancer.
  • The absence of radiographic change after 6 months of chemotherapy led to resection of the breast and lung lesions.
  • A complete central nervous system evaluation eliminated other locations of meningioma, allowing the diagnosis of primary pulmonary meningioma.
  • [MeSH-major] Lung Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797095.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Demirci H, Marentette LJ, Nelson CC: The transglabellar/subcranial approach for surgical excision of periocular second tumors in retinoblastoma. Orbit; 2008;27(4):285-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transglabellar/subcranial approach for surgical excision of periocular second tumors in retinoblastoma.
  • PURPOSE: To evaluate the use of transglabellar/subcranial approach for surgical resection of periocular second non-ocular tumors in retinoblastoma patients.
  • METHODS: Seven retinoblastoma patients with periocular second tumor involving anterior skull base underwent surgical resection by transglabellar/subcranial approach in a single center.
  • RESULTS: The most common presenting symptom in retinoblastoma patients with periocular second tumor was difficulty in maintaining the prosthesis in three patients (43%), followed by epistaxis in one (14%), palpable orbital mass in one (14%), persistent periocular swelling in one (14%), and visual loss in one (14%) patient.
  • Periocular second tumors were leiomyosarcoma in three (43%) patients, osteosarcoma in three (43%), and sphenoid wing meningioma in one (14%) patient.
  • Surgical resection by the transglabellar/subcranial approach was the only treatment in one (14%) patient with sphenoid wing meningioma and was combined with chemotherapy in three (43%) patients, and with both external beam radiotherapy and chemotherapy in three (43%) patients.
  • CONCLUSIONS: Retinoblastoma patients with periocular second tumors have a poor prognosis.
  • The transglabellar/subcranial approach can be used for surgical resection of periocular second tumor involving skull base with low morbidity.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Eye Enucleation. Eyebrows. Female. Frontal Bone. Humans. Leiomyosarcoma / surgery. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / surgery. Meningioma / surgery. Middle Aged. Orbital Neoplasms / surgery. Osteosarcoma / surgery. Paranasal Sinus Neoplasms / surgery. Radiotherapy. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Retinoblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716966.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Rao G, Klimo P Jr, Jensen RL, MacDonald JD, Couldwell WT: Surgical strategies for recurrent craniofacial meningiomas. Neurosurgery; 2006 May;58(5):874-80; discussion 874-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for recurrent craniofacial meningiomas.
  • OBJECTIVE: Recurrent cranial base meningiomas are among the most difficult tumors to treat surgically.
  • Although they are histologically benign, these tumors often invade through the cranial base into the infratemporal and pterygopalatine fossae.
  • We reviewed our experience with these tumors to describe the natural history of these lesions as well as provide a possible treatment paradigm.
  • METHODS: Between 2000 and 2004, seven patients with meningiomas recurring through the cranial base into facial structures were treated at the University of Utah.
  • Five patients were treated with transcranial approaches only, and two were treated with a combination of transcranial and transfacial approaches.
  • The original site of tumor was the sphenoid wing in four patients, the middle fossa in two patients, and the left frontal region in one patient.
  • The average interval between the most recent tumor resection and recurrence into the face was 9.9 years.
  • All but one patient had adjunctive therapy (including either radiation or chemotherapy) before recurrence into the face.
  • CONCLUSION: Meningiomas that recur into facial structures present a unique treatment challenge.
  • [MeSH-major] Facial Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Skull Base Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639321.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Struhal W, Oberndorfer S, Lahrmann H, Lindeck-Pozza E, Hess B, Nussgruber V, Pöhnl R, Dobner T, Grisold W: Myeloid sarcoma in the central nervous system: case report and review of the literature. Acta Clin Croat; 2008 Mar;47(1):19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case is added herewith and a review was performed to investigate clinical characteristics and treatment options of central nervous system myeloid sarcoma.
  • A 61-year-old female with acute myeloblastic leukemia (FAB M5) and progressive left sided hemiparesis showed a right parieto-occipital epidural lesion mimicking meningioma.
  • Reviewing the literature we identified 44 cases with sufficient description of the diagnosis, treatment and follow up to one year.
  • In these patients different treatment regimens were applied.
  • However, when systemic chemotherapy or irradiation was included in the treatment regimen, patients showed the best 1-year survival proportion.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary. Occipital Lobe. Parietal Lobe. Sarcoma, Myeloid / diagnosis

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18714643.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 20
  •  go-up   go-down


23. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R: Management of patients receiving long-term treatment with mifepristone. Fertil Steril; 2005 Dec;84(6):1719-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of patients receiving long-term treatment with mifepristone.
  • OBJECTIVE: To determine clinical side effects and biochemical and hematological abnormalities in patients with nonresectable meningioma on long-term mifepristone (RU 486) therapy.
  • DESIGN: Long-term mifepristone administration in patients with meningioma.
  • PATIENT(S): Sixteen women and 9 men aged 22-80 years with nonresectable meningioma.
  • One patient received treatment for more than 13 years; six received treatment for 10-12 years; five received treatment for 4-9 years; eight received treatment for 1-4 years; and the remainder received treatment for 4-10 months.
  • One subject (on long-term dexamethasone) developed hypoadrenalism, which responded to treatment.
  • Because biochemical hypothyroidism has been reported during long-term mifepristone therapy, thyroid function tests should be performed annually.
  • [MeSH-major] Hormone Antagonists / administration & dosage. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Mifepristone / administration & dosage
  • [MeSH-minor] Adrenal Insufficiency / chemically induced. Adrenal Insufficiency / pathology. Adult. Aged. Aged, 80 and over. Amenorrhea / chemically induced. Amenorrhea / pathology. Drug Monitoring / methods. Endometrial Hyperplasia / chemically induced. Endometrial Hyperplasia / pathology. Female. Humans. Male. Middle Aged. Time Factors


24. Heran NS, Yong RL, Heran MS, Yip S, Fairholm D: Primary intradural extraarachnoid hodgkin lymphoma of the cervical spine. Case report. J Neurosurg Spine; 2006 Jul;5(1):61-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On imaging studies the lesion mimicked the appearance of a meningioma.
  • At surgery, the mass was found to be an intradural extra-arachnoid tumor.
  • The procedure was limited to biopsy sampling and the patient was treated further with adriamycin, bleomycin, vincristine, and dacarbazine chemotherapy, after which remission was demonstrated both clinically and on images.
  • Analysis of a frozen section obtained during the procedure aided in the diagnosis of the tumor, thus preventing further resection and the potential neurological complications associated with more radical resection.
  • [MeSH-major] Hodgkin Disease / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850958.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Collins IM, Beddy P, O'Byrne KJ: Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor. Acta Oncol; 2010 Aug;49(6):872-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Incidental Findings. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / radiography. Meningioma / drug therapy. Meningioma / radiography. Receptor, IGF Type 1 / antagonists & inhibitors
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Clinical Trials, Phase I as Topic. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Immunoglobulins, Intravenous. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429732.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Immunoglobulins, Intravenous; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Receptor, IGF Type 1; Q20Q21Q62J / Cisplatin; VE267FC2UB / figitumumab
  •  go-up   go-down


27. Di Patre PL, Radziszewski W, Martin NA, Brooks A, Vinters HV: A meningioma-mimicking tumor caused by Mycobacterium avium complex in an immunocompromised patient. Am J Surg Pathol; 2000 Jan;24(1):136-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meningioma-mimicking tumor caused by Mycobacterium avium complex in an immunocompromised patient.
  • Intracranial tuberculomas manifesting radiologically as typical dural-based "meningiomas" have been reported, most frequently in immunosuppressed patients.
  • According to published reports, intracranial tuberculomas are always due to infection by Mycobacterium tuberculosis.
  • We report a case of a 50-year-old woman with systemic lupus erythematosus (SLE) who presented with a dural based, meningioma-like mass in the right frontal region, resulting from a localized infection by Mycobacterium avium complex.
  • Histologically, the mass resembled a meningioma in being composed of spindly cells arranged in a fascicular pattern.
  • Immunohistochemical stains showed this tumor to consist of a large aggregate of AFB-laden histiocytes without caseating necrosis or multinucleated giant cells.
  • [MeSH-major] Immunocompromised Host. Mycobacterium avium-intracellulare Infection / diagnosis. Tuberculoma, Intracranial / diagnosis
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Azathioprine / therapeutic use. Female. Humans. Immunohistochemistry. Immunosuppressive Agents / therapeutic use. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Middle Aged. Prednisone / therapeutic use. Tomography, X-Ray Computed


28. Kutschenko A, Liebetanz D: Meningioma causing gabapentin-responsive secondary SUNCT syndrome. J Headache Pain; 2010 Aug;11(4):359-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma causing gabapentin-responsive secondary SUNCT syndrome.
  • Cases of symptomatic SUNCT syndromes are reported, which demonstrate that brain imaging is very important for diagnosis.
  • In this study, we describe the first case of secondary SUNCT syndrome caused by a meningioma.
  • So far, a clearly effective therapy for SUNCT syndrome has not been known.
  • This underlines that this drug is worthy of being considered as a potential therapeutic option in the treatment of SUNCT syndrome.
  • [MeSH-major] Amines / therapeutic use. Analgesics / therapeutic use. Cyclohexanecarboxylic Acids / therapeutic use. Meningeal Neoplasms / complications. Meningioma / complications. SUNCT Syndrome / etiology. gamma-Aminobutyric Acid / therapeutic use

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. GABAPENTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2006 Oct;129(Pt 10):2746-60 [16905753.001]
  • [Cites] Cephalalgia. 2007 Jul;27(7):824-32 [17598764.001]
  • [Cites] Curr Pain Headache Rep. 2008 Apr;12(2):132-7 [18474194.001]
  • [Cites] Eur J Neurol. 2006 Oct;13(10):1066-77 [16987158.001]
  • [Cites] Neurology. 2002 Jun 11;58(11):1698-9 [12058109.001]
  • [Cites] Cephalalgia. 1989 Jun;9(2):147-56 [2743414.001]
  • [Cites] Cephalalgia. 2006 May;26(5):620-2 [16674773.001]
  • [Cites] Cephalalgia. 2008 Dec;28(12):1339-42 [18727639.001]
  • (PMID = 20428918.001).
  • [ISSN] 1129-2377
  • [Journal-full-title] The journal of headache and pain
  • [ISO-abbreviation] J Headache Pain
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Amines; 0 / Analgesics; 0 / Cyclohexanecarboxylic Acids; 56-12-2 / gamma-Aminobutyric Acid; 6CW7F3G59X / gabapentin
  • [Other-IDs] NLM/ PMC2917557
  •  go-up   go-down


29. Fukushima Y, Oka H, Utsuki S, Iwamoto K, Fujii K: Nevoid Basal cell carcinoma syndrome with medulloblastoma and meningioma--case report. Neurol Med Chir (Tokyo); 2004 Dec;44(12):665-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid Basal cell carcinoma syndrome with medulloblastoma and meningioma--case report.
  • A 35-year-old man presented with a rare case of nevoid basal cell carcinoma syndrome, or Gorlin's syndrome, associated with both medulloblastoma and meningioma, manifesting as visual field constriction due to multiple parasellar tumors.
  • He had undergone resection of a medulloblastoma at the age of 1 year 9 months, followed by adjunctive irradiation with a total dose of 40 Gy.
  • Histological examination of biopsy specimens established the diagnosis of nevoid basal cell carcinoma syndrome.
  • Tuberculum sellae meningioma was removed through a craniotomy, and his symptoms improved.
  • Meningioma is known to occur in the field of therapeutic irradiation, so chemotherapy may be a better option for medulloblastoma associated with nevoid basal cell carcinoma syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome. Cerebellar Neoplasms. Medulloblastoma. Meningeal Neoplasms. Meningioma. Neoplasms, Second Primary


30. Schöfl C, Schöfl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS, Samii M, von zur Mühlen A, Brabant G: Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary; 2002;5(4):261-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of tumors at the base of the skull comprises meningiomas, neurinomas, gliomas, metastatic carcinomas, chordomas, epidermoids, and pituitary adenomas.
  • About half of the pituitary adenomas are prolactinomas which are unique in a sense that medical therapy causes rapid tumor shrinkage and symptomatic improvement.
  • We report on two patients in which the diagnosis of an invasive macroprolactinoma was masked by apparently low prolactin levels caused by a high-dose hook effect in the chemiluminometric assay.
  • A massive invasively growing tumor was demonstrated on a cranial MRI.
  • The histopathological diagnosis was invasive prolactinoma.
  • Dopamine agonist therapy was initiated under which PRL levels declined in parallel with tumor size.
  • Cranial MRI showed a large tumor at the base of the skull.
  • Based on a transnasal biopsy, the preliminary diagnosis was a poorly differentiated carcinoma for which emergency irradiation was performed.
  • Hydrocortisone was substituted and dopamine agonist therapy was started because of moderate hyperprolactinemia.
  • The final histopathological diagnosis was invasive prolactinoma.
  • A repeat PRL sample assayed in serial dilution demonstrated an apparent rise in PRL with a maximum value of 6,460 ng/ml.
  • Under dopamine agonist therapy, PRL declined to normal values, tumor size decreased and cranial nerve palsies disappeared.
  • Serial dilutions of serum PRL samples is, therefore, mandatory in the diagnostic work-up of patients with large invasive tumors at the base of the skull.
  • This avoids unnecessary aggressive and dangerous treatment like surgery or radiotherapy in cases where pharmacological treatment may be the choice.
  • [MeSH-minor] Adult. Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. False Negative Reactions. Headache / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Pituitary Function Tests. Skull Base Neoplasms / blood. Skull Base Neoplasms / drug therapy. Skull Base Neoplasms / pathology. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Mar;44(3):305-9 [8729527.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):1789-93 [10843153.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2381-5 [9253304.001]
  • [Cites] N Engl J Med. 1985 Sep 12;313(11):656-9 [4022058.001]
  • [Cites] Arch Intern Med. 1993 Sep 27;153(18):2165, 2168 [8379808.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Mar;34(3):231-5 [2036731.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):913-5; discussion 915-6 [9574657.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22 [10404830.001]
  • (PMID = 14558675.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  •  go-up   go-down


31. Lallana EC, Abrey LE: Update on the therapeutic approaches to brain tumors. Expert Rev Anticancer Ther; 2003 Oct;3(5):655-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the therapeutic approaches to brain tumors.
  • The understanding of brain tumors has expanded in pace with advances in the field of molecular biology and genetics.
  • Diagnoses are more accurate, biopsy and surgical intervention safer, radiotherapy more focused and chemotherapy safer and better tolerated.
  • Novel strategies based on the understanding of brain tumor biology are emerging as targeted approaches to therapy.
  • Despite all this, only a minority of patients with certain subsets of brain tumors have experienced prolonged survival.
  • This review focuses on the standard and emerging therapies for the two most common categories of brain tumors: gliomas and meningiomas.
  • Primary CNS lymphoma, while a relatively rare tumor, is also included as a topic of discussion as the achievements in its treatment represent the principal strides in the evolution of neuro-oncology.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Animals. Antibodies, Monoclonal / therapeutic use. Boron Neutron Capture Therapy. Combined Modality Therapy. Glioma / drug therapy. Glioma / therapy. Humans. Meningioma / drug therapy. Meningioma / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599089.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Number-of-references] 139
  •  go-up   go-down


32. Jensen RL, Wurster RD: Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice. Surg Neurol; 2001 May;55(5):275-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice.
  • BACKGROUND: We have previously shown that calcium channel antagonists inhibit in vitro meningioma growth.
  • This study examines the effect of calcium channel antagonists on in vivo xenograft meningioma growth.
  • METHODS: Meningioma cells taken from human patients were mixed with Matrigel and injected into the subcutaneous space in the flank of nude mice.
  • Tumor volumes were measured over time; comparison was made between control and treatment groups.
  • Comparison of histology and proliferation index was made between control and treatment groups.
  • RESULTS: Diltiazem treatment decreased tumor growth over time compared to control groups.
  • Increased tumor growth inhibition was seen with increasing doses (p > 0.05).
  • Treatment with verapamil had similar effects; however, there are no statistically significant dose dependent decreases in growth with increasing verapamil doses.
  • There were no tumor "cures" or spontaneous regression of tumor in any group including the control groups.
  • Mouse serum drug levels increased with increasing doses of drug in the drinking water of treatment groups (p > 0.05).
  • Histology and proliferative index of treatment groups were similar to control groups.
  • CONCLUSION: Calcium channel antagonists decrease but do not completely inhibit the growth of meningiomas in nude mice.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Calcium Channel Blockers / pharmacology. Meningioma / drug therapy
  • [MeSH-minor] Animals. Biocompatible Materials. Collagen. Diltiazem / pharmacology. Dose-Response Relationship, Drug. Drug Combinations. Humans. Immunohistochemistry. Ki-67 Antigen. Laminin. Male. Meningeal Neoplasms / drug therapy. Mice. Mice, Nude. Proteoglycans. Transplantation, Heterologous. Verapamil / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DILTIAZEM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11516467.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biocompatible Materials; 0 / Calcium Channel Blockers; 0 / Drug Combinations; 0 / Ki-67 Antigen; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; CJ0O37KU29 / Verapamil; EE92BBP03H / Diltiazem
  •  go-up   go-down


33. Rockhill J, Mrugala M, Chamberlain MC: Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus; 2007;23(4):E1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas: an overview of diagnosis and treatment.
  • Meningiomas are extraaxial central nervous system tumors most often discovered in middle to late adult life, and are more often seen in women.
  • Ninety percent of meningiomas are benign, 6% are atypical, and 2% are malignant.
  • Most patients in whom a meningioma is diagnosed undergo resection to relieve neurological symptoms.
  • For the majority of incompletely resected or recurrent tumors not previously irradiated, radiotherapy is administered.
  • Radiotherapy may be administered as either conventional external-beam radiation therapy or stereotactically by linear accelerator, Leksell Gamma Knife, or Cyberknife radiosurgery.
  • Advocates of stereo-tactic radiotherapy have suggested this therapy in lieu of surgery particularly in high-risk patients, those with meningiomas in eloquent or surgically inaccessible locations, and elderly patients.
  • When the meningioma is unresectable or all other treatments (surgery and radiotherapy) have failed, hormonal therapy or chemotherapy may be considered.
  • Notwithstanding limited data, hydroxyurea has been modestly successful in patients with recurrent meningiomas.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961033.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


34. Morita K, Matsuzawa H, Fujii Y, Tanaka R, Kwee IL, Nakada T: Diffusion tensor analysis of peritumoral edema using lambda chart analysis indicative of the heterogeneity of the microstructure within edema. J Neurosurg; 2005 Feb;102(2):336-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Histopathological studies indicate that cerebral edema associated with tumors (peritumoral edema) does not represent a single pathophysiological or clinical entity.
  • In this study the authors investigated peritumoral edema by performing lambda chart analysis (LCA), a noninvasive technique that can be used to make visible and analyze apparent water diffusivity in tissues in vivo, and assessed the utility of LCA in differentiating high-grade gliomas from nonglial tumors.
  • METHODS: The water diffusivity characteristics of peritumoral edema associated with four tumor groups-12 high-grade gliomas, five low-grade gliomas, 11 metastatic tumors, and 15 meningiomas-were assessed in 43 patients by performing magnetic resonance imaging with the aid of a 3-tesla magnetic resonance imaging system.
  • In all tumor groups, peritumoral edema exhibited greater trace values and reduced anisotropy compared with normal white matter.
  • Edema associated with high-grade gliomas had significantly higher trace values than edema associated with the other three tumor groups, although the anisotropic angles of those groups were comparable.
  • CONCLUSIONS: Lambda chart analysis identified two distinct types of peritumoral edema: edema associated with high-grade gliomas and edema associated with low-grade gliomas or nonglial tumors.
  • The apparent water diffusivity was significantly greater in high-grade gliomas, whereas the anisotropy in these lesions was comparable to that of edema in other tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging. Glioma / pathology. Image Processing, Computer-Assisted. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anisotropy. Brain / pathology. Child. Computer Graphics. Female. Humans. Male. Mathematical Computing. Middle Aged. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739563.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Tu PH, Giannini C, Judkins AR, Schwalb JM, Burack R, O'Neill BP, Yachnis AT, Burger PC, Scheithauer BW, Perry A: Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol; 2005 Aug 20;23(24):5718-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma.
  • The aim of this study is to elucidate the biology and genetic features of this unusual tumor.
  • RESULTS: CNS MZBCLs preferentially affect middle-aged women (female-to-male ratio, 4:1), with 93% presenting as dural-based masses mimicking meningioma.
  • Ten patients with 1 to 7.6 years of follow-up after diagnosis showed no evidence of disease after radiation and/or chemotherapy.
  • CONCLUSION: Our data suggest that intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-like dural-based mass.
  • Trisomy 3, but not MALT1 or IgH translocation, is a common genetic abnormality that may contribute to the pathogenesis of this CNS lymphoma.
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 3. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Meningioma / pathology. Middle Aged. Translocation, Genetic. Trisomy

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009945.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Scherer K, Johnston J, Panda M: Dural based mass: malignant or benign. J Radiol Case Rep; 2009;3(11):1-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural based mass: malignant or benign.
  • In March 2007, a 68 year old female was diagnosed with colonic adenocarcinoma metastatic to the lungs and a frontoparietal parafalcine lesion suspected to be a meningioma was also noted.
  • For 14 months, she received chemotherapy with poor response.
  • In June 2008, she developed multiple focal neurologic deficits.
  • Enlargement of the parafalcine brain lesion was noted on head computerized tomography and magnetic resonance imaging.
  • Cerebral angiogram demonstrated a parafalcine mass supplied by the middle meningeal artery.
  • All 3 modality findings confirmed a meningioma.
  • Embolization of the middle meningeal artery with craniotomy for excision of the suspected meningioma was performed.
  • Pathology indicated metastatic adenocarcinoma with colonic primary without evidence of meningioma.
  • Meningiomas are the most common dural based lesions; however, a variety of dural lesions mimic meningiomas.
  • Dural metastatic tumors mimicking meningiomas is an uncommon phenomenon, particularly when the primary location is the colon.
  • This paper additionally discusses the differentiation of benign dural based tumors like meningiomas from malignant findings.
  • Multiple adjunct studies can differentiate meningiomas from metastatic tumor.
  • The definitive diagnosis is based on histopathology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Dec;33(12):1211-26 [12514791.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33 [12591638.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jun;44(6):317-20 [15253548.001]
  • [Cites] Acta Cytol. 1981 Sep-Oct;25(5):461-79 [7025541.001]
  • [Cites] Acta Cytol. 1981 Nov-Dec;25(6):599-610 [6947665.001]
  • [Cites] Neurosurgery. 1986 Nov;19(5):820-3 [3785633.001]
  • [Cites] J Neurosurg Sci. 1987 Jan-Mar;31(1):33-6 [3625287.001]
  • [Cites] Neuroradiology. 1993;35(4):272-3 [8492892.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Feb;34(2):108-10 [7514757.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):345-67 [8823768.001]
  • [Cites] Surg Neurol. 2002 Sep-Oct;58(3-4):241-5 [12480230.001]
  • [Cites] Otol Neurotol. 2002 Nov;23(6):975-9 [12438865.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):193-9 [12187955.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jul;125(7):880-7 [11419971.001]
  • [Cites] Australas Radiol. 2005 Dec;49(6):497-500 [16351616.001]
  • [Cites] Clin Neurol Neurosurg. 1997 May;99(2):135-7 [9213059.001]
  • [Cites] Neurologist. 2006 Jan;12(1):48-52 [16547447.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):57-61 [16215816.001]
  • [Cites] Neurochirurgie. 1999 May;45(2):160-3 [10448659.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):552-8 [9761048.001]
  • (PMID = 22470624.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303278
  • [Keywords] NOTNLM ; Dural based mass / meningioma / metastatic dural based lesions
  •  go-up   go-down


37. Rutter MM, Rose SR: Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr; 2007 Aug;19(4):480-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Endocrine deficiencies are common after cranial irradiation, chemotherapy and specific tumors.
  • Risks for obesity after childhood tumors include hypothalamic injury, with inactivity and daytime sleepiness.
  • Treatment with growth hormone does not increase cancer recurrence, but survivors may have a 2-fold risk of developing a secondary solid tumor, most commonly a meningioma.
  • SUMMARY: Standardized, multidisciplinary long-term surveillance is important in childhood cancer survivors to identify and treat endocrine and other late effects of cancer and its therapy.
  • [MeSH-major] Endocrine Glands / drug effects. Endocrine Glands / radiation effects. Neoplasms / complications. Neoplasms / therapy. Survivors
  • [MeSH-minor] Child. Combined Modality Therapy. Female. Gonads / drug effects. Gonads / radiation effects. Hematopoietic Stem Cell Transplantation. Humans. Male. Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Second Primary / epidemiology. Obesity / epidemiology. Patient Care Team. Population Surveillance. Thyroid Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630615.001).
  • [ISSN] 1040-8703
  • [Journal-full-title] Current opinion in pediatrics
  • [ISO-abbreviation] Curr. Opin. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


38. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD: Medical therapies for meningiomas. J Neurooncol; 2010 Sep;99(3):365-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical therapies for meningiomas.
  • Meningiomas are the most common primary brain tumor in adults.
  • Although the majority of these tumors can be effectively treated with surgery and radiation therapy, an important subset of patients have inoperable tumors, or develop recurrent disease after surgery and radiotherapy, and require some form of medical therapy.
  • There are increasing numbers of studies evaluating various medical therapies but the results remain disappointing.
  • Chemotherapies and hormonal therapies have been generally ineffective, although somatostatin analogues may have therapeutic potential.
  • There is also increasing interest in targeted molecular therapies.
  • As with other tumors, advances in the medical therapies for meningiomas will require improved understanding of the molecular pathogenesis of these tumors, more predictive preclinical models, and efficient mechanisms for conducting clinical trials, given the small population of eligible patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cranial Irradiation. Meningeal Neoplasms / therapy. Meningioma / therapy. Radiosurgery

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1998 May;88(5):938-9 [9576275.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):161-2 [15762200.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):207-16 [8858526.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):304-10 [18240927.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):668-75 [12296652.001]
  • [Cites] Cancer Treat Rev. 2006 Oct;32(6):407-16 [16889900.001]
  • [Cites] N Engl J Med. 2007 Dec 6;357(23):2411-2 [18057351.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):279-82 [18182668.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Neurosurgery. 2007 Apr;60(4):750-9; discussion 759-60 [17415213.001]
  • [Cites] Skull Base. 2008 May;18(3):173-87 [18978964.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4074-82 [15930342.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] Neurosurg Rev. 2004 Oct;27(4):238-45 [15168138.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):471-6 [17580362.001]
  • [Cites] Cancer Treat Rev. 2006 May;32(3):157-65 [16516391.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 May;6(5):679-95 [16759160.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):5-10 [15651171.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1547-53 [15735044.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] J Clin Invest. 1995 Oct;96(4):2017-25 [7560095.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):109-22 [17624496.001]
  • [Cites] Acta Oncol. 2010 Aug;49(6):872-4 [20429732.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):183-92 [12242151.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] CA Cancer J Clin. 2005 May-Jun;55(3):178-94 [15890640.001]
  • [Cites] Oncogene. 2008 Oct 20;27(48):6252-75 [18931692.001]
  • [Cites] J Neurooncol. 1995;23 (1):23-9 [7542695.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1770-83 [16603719.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Apr;5(2):355-78 [15877531.001]
  • [Cites] Curr Drug Targets. 2010 Mar;11(3):291-302 [20210754.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):289-301 [9440026.001]
  • [Cites] Neurosurgery. 2007 May;60(5):787-98; discussion 787-98 [17460514.001]
  • [Cites] Expert Rev Neurother. 2004 Jul;4(4):641-8 [15853583.001]
  • [Cites] J Neurooncol. 2014 Mar;117(1):93-101 [24449400.001]
  • [Cites] Curr Treat Options Neurol. 2004 Jul;6(4):297-305 [15157407.001]
  • [Cites] J Pathol. 1999 Sep;189(1):66-71 [10451490.001]
  • [Cites] J Clin Oncol. 2010 Feb 20;28(6):1075-83 [20085938.001]
  • [Cites] Cancer Control. 2003 Mar-Apr;10(2):148-58 [12712009.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] Neurology. 2004 Sep 28;63(6):1133-4 [15452322.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] Neurosurgery. 2000 Nov;47(5):1185-95 [11063113.001]
  • [Cites] Expert Rev Mol Diagn. 2006 Jul;6(4):613-26 [16824034.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):455-62 [17367069.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E9 [17961046.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E11 [17961035.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E10 [17961034.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] J Clin Neurosci. 2002 Mar;9(2):156-8 [11922703.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Apr;5(2):333-42 [15877529.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):155-66 [15015781.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] Nat Rev Cancer. 2009 Aug;9(8):550-62 [19629070.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Nov;187(1):25-7 [18992637.001]
  • [Cites] Expert Opin Investig Drugs. 2008 Aug;17 (8):1225-35 [18616418.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Neurosurgery. 1997 May;40(5):1016-26 [9149260.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):505-15 [16069815.001]
  • [Cites] Endocr Relat Cancer. 2008 Dec;15(4):931-41 [18632875.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Cell Mol Life Sci. 2007 Feb;64(4):458-78 [17260089.001]
  • [Cites] Cancer Lett. 2004 Sep 15;213(1):117-24 [15312691.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] J Neurosurg. 1997 May;86(5):845-52 [9126901.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • [Cites] Neurosurgery. 2000 Apr;46(4):938-47; discussion 947-8 [10764269.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):487-92 [11235955.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2611-4 [9205065.001]
  • [Cites] Eur J Cancer. 1991;27(4):416-9 [1828169.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17 (10 ):2663-70 [18843008.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):493-505 [10898356.001]
  • [Cites] J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S135-9 [11078359.001]
  • [Cites] CA Cancer J Clin. 2010 Jul-Aug;60(4):222-43 [20554717.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1269-77 [9179901.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6):1034-40 [17564176.001]
  • [Cites] Neuroimaging Clin N Am. 2010 Aug;20(3):425-48 [20708556.001]
  • [Cites] Expert Rev Neurother. 2006 Oct;6(10):1447-64 [17078786.001]
  • [Cites] Neurosurgery. 1998 Oct;43(4):890-8; discussion 898-9 [9766317.001]
  • [Cites] Hybridoma. 2001 Apr;20(2):131-6 [11394532.001]
  • [Cites] Int J Oncol. 2008 Nov;33(5):937-47 [18949356.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):269-72 [8858533.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):91-100 [17150037.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):19-26 [12125963.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):45-51 [8583244.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9394-407 [16361639.001]
  • [Cites] Front Biosci (Elite Ed). 2009 Jun 01;1:494-500 [19482663.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Cancer Invest. 2006 Dec;24(8):727-33 [17162554.001]
  • [Cites] Am J Clin Oncol. 2009 Feb;32(1):73-85 [19194129.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):306-14 [10659019.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):25-32 [16773181.001]
  • [Cites] Hum Reprod. 1994 Jun;9 Suppl 1:202-7 [7962466.001]
  • [Cites] J Neurooncol. 2009 Mar;92(1):1-6 [19023520.001]
  • [Cites] Curr Neurol Neurosci Rep. 2009 May;9(3):231-40 [19348712.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):782-98 [18813321.001]
  • [Cites] Surg Neurol. 1985 Sep;24(3):245-9 [4023903.001]
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):488-96 [8211601.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4033-42 [17827451.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S131-4 [11762340.001]
  • [Cites] J Nucl Med. 2005 May;46(5):763-9 [15872348.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):121-32 [18202696.001]
  • [Cites] J Neurooncol. 2010 Jan;96(2):211-7 [19562255.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):440-6 [10470819.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2146-51 [18756531.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2005;22:123-33 [16110610.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3749-55 [14506167.001]
  • [Cites] Cancer Biol Ther. 2004 Mar;3(3):247-50 [15107611.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] BMC Cancer. 2006 Jun 07;6:152 [16759391.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2411-22 [15800333.001]
  • [Cites] Neurology. 1975 Aug;25(8):705-12 [1171403.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:49-53 [11386826.001]
  • [Cites] J Neurosurg Sci. 1993 Dec;37(4):237-41 [7931648.001]
  • [Cites] Brain Pathol. 2008 Apr;18(2):172-9 [18093250.001]
  • [Cites] Neurosurg Clin N Am. 2006 Apr;17(2):111-20, vi [16793503.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):839-44 [11702875.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • [Cites] J Nucl Med. 1998 Nov;39(11):1913-7 [9829583.001]
  • (PMID = 20820875.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


39. Reubi JC: In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci; 2000;921:1-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications.
  • The evaluation of peptide receptors in man is relevant to identifying the physiological target tissues of a given peptide and to selecting diseases with a sufficient receptor overexpression for diagnostic or therapeutic intervention.
  • VIP/PACAP receptors have been evaluated in normal and diseased human non-neuronal tissues by using in vitro receptor autoradiography with 125I-VIP or 125I-PACAP in tissue sections.
  • As assessed by subtype-selective VIP analogs, VIP receptors of the VPAC1 subtype are found in a wide variety of tissues including liver, breast, kidney, prostate, ureter, bladder, pancreatic ducts, gastrointestinal mucosa, lung, thyroid, adipose, and lymphoid tissues.
  • VIP/PACAP receptors are expressed in the majority of the most frequently occurring human tumors, including breast, prostate, pancreas, lung, colon, stomach, liver, and bladder carcinomas, as well as lymphomas and meningiomas, predominantly as VPAC1 receptors, as do their tissues of origin.
  • Although leiomyomas predominantly express VPAC2 receptors, glial tumors, pituitary adenomas, neuroblastomas, paragangliomas, pheochromocytomas, and endometrial carcinomas preferentially express PAC1 receptors.
  • Moreover, the receptor expression in tumors is the molecular basis for clinical applications of VIP/PACAP such as in vivo scintigraphy and radiotherapy of tumors as well as VIP/PACAP analog treatment for tumor growth inhibition.
  • [MeSH-minor] Autoradiography. Epithelium / metabolism. Female. Humans. In Vitro Techniques. Male. Neoplasm Metastasis. Neoplasms / drug therapy. Neoplasms / metabolism. Neoplasms / radiotherapy. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I. Receptors, Vasoactive Intestinal Peptide, Type II. Receptors, Vasoactive Intestinal Polypeptide, Type I. Tissue Distribution


40. Meester-Smoor MA, Janssen MJ, Grosveld GC, de Klein A, van IJcken WF, Douben H, Zwarthoff EC: MN1 affects expression of genes involved in hematopoiesis and can enhance as well as inhibit RAR/RXR-induced gene expression. Carcinogenesis; 2008 Oct;29(10):2025-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The oncoprotein meningioma 1 (MN1) is overexpressed in several subtypes of acute myeloid leukemia (AML) and overexpression was associated with a poor response to chemotherapy.
  • [MeSH-major] Hematopoiesis. Receptors, Retinoic Acid / physiology. Retinoid X Receptors / physiology. Tumor Suppressor Proteins / physiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Mar 15;277(11):8989-98 [11779847.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5733-40 [17369854.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):919-23 [12584571.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4074-82 [12821941.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Blood. 2004 Aug 1;104(3):675-86 [15090461.001]
  • [Cites] Int J Cancer. 1976 May 15;17(5):565-77 [178611.001]
  • [Cites] Cell. 1991 May 31;65(5):737-52 [1904008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2105-9 [1347945.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1511-9 [7731705.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] Science. 1995 Jun 23;268(5218):1766-9 [7792603.001]
  • [Cites] Leukemia. 1997 Jan;11(1):54-63 [9001419.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1236-47 [9488438.001]
  • [Cites] J Biol Chem. 1999 Oct 15;274(42):30132-8 [10514502.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3679-87 [15226186.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3705-6 [15297296.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R93-R100 [15809278.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):871-7 [10544023.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(24):9281-93 [11094079.001]
  • [Cites] Oncogene. 2001 Feb 15;20(7):874-8 [11314021.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]
  • [Cites] Int J Hematol. 2005 Jul;82(1):42-7 [16105758.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D684-8 [16381959.001]
  • [Cites] Blood Rev. 2006 Mar;20(2):71-82 [16185796.001]
  • [Cites] Am J Hematol. 2006 Apr;81(4):227-35 [16550517.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2434-41 [16638849.001]
  • [Cites] Blood. 2006 Jul 15;108(2):622-9 [16469876.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1582-92 [16810199.001]
  • [Cites] Curr Opin Genet Dev. 2006 Oct;16(5):496-501 [16919448.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3898-905 [16912223.001]
  • [Cites] Carcinogenesis. 2006 Dec;27(12):2355-66 [16920733.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8317-24 [17244623.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5148-55 [17545593.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1679-90 [17525718.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1639-47 [17494859.001]
  • [Cites] Oncogene. 2003 Feb 6;22(5):699-709 [12569362.001]
  • (PMID = 18632758.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072996
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / ETS translocation variant 6 protein; 0 / ITGAM protein, human; 0 / MN1 protein, human; 0 / Proto-Oncogene Proteins c-ets; 0 / Receptors, Retinoic Acid; 0 / Repressor Proteins; 0 / Retinoid X Receptors; 0 / Tumor Suppressor Proteins; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ PMC3202306
  •  go-up   go-down


41. Turowski B, Zanella FE: Interventional neuroradiology of the head and neck. Neuroimaging Clin N Am; 2003 Aug;13(3):619-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular interventions are important and helpful for treatment of various pathologies of the head and neck.
  • Interventional neuroradiology of the head and neck includes image-guided biopsies, vessel occlusion, and local chemotherapy.
  • Knowledge of anatomy, functional relationships between intra- and extracranial vessels, and pathology are the basis for therapeutic success.
  • Neuroradiologic imaging, especially CT and MR imaging, and appropriate analysis of angiographic findings help ensure indication for treatment and plan an intervention.
  • Indications for image-guided biopsies are preverterbal fluid-collections, spinal and paraspinal inflammations and abscesses, deep cervical malignancies, vertebral body, and skull base tumors.
  • Indications for vessel occlusion are emergency situations to stop bleeding in vascular lesions (traumatic, malformation, or tumors) by reduction of pressure, preoperative reduction of blood flow to minimize the surgical risk, palliative occlusion of feeding vessels to produce tumor necrosis, or potential curative (or presurgical) occlusion of vascular malformations.
  • Examples of these interventions are: a hemangioma of the hard palate, a juvenile angiofibroma, a hemangiopericytoma, a malignant meningioma, a malignant fibrous histiocytoma, and a glomus tumor.
  • Effective treatment of vascular malformations, such as AV fistulas or angiomas, needs exact occlusion of the fistula or the angiomatous nidus, which is demonstrated in the case of an AV angioma of the base of the tongue.
  • Chemotherapy with local intra-arterial cisplatin combined with intravenous administration of sodium thiosulfate as antidote is indicated as an adjuvant modality in a multimodal regimen of oropharyngeal squamous cell carcinoma or as palliative treatment of recurrent and otherwise untreatable malignant tumors of the head and neck.
  • Palliative treatment of a bleeding oropharyngeal cancer is another example of interventional treatment.
  • Selective treatment, either occluding or pharmacologic, may be preoperative, palliative, or curative.
  • The objective is reduction of surgical risk, improvement of quality of life, or curative therapy of a lesion.
  • Thus, the interventional treatment should not be associated with morbidity or mortality.
  • The benefits, risks, and expected damages of neuroradiologic interventions must be balanced during the informed consent procedure with the patient.
  • [MeSH-major] Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / therapy. Neuroradiography. Radiology, Interventional

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631695.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


42. Saeger W: [Pituitary gland tumors]. Pathologe; 2003 Jul;24(4):255-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pituitary gland tumors].
  • Pituitary adenomas must be clearly differentiated from other tumors of the sellar region (especially meningiomas, granular cell tumors, chordomas and germinomas), which may look very similar.
  • This sub-classification is not necessary in every case, but must be performed if unusual findings are observed during surgery or if surgery is unsuccessful and radiation or drug-therapy is planned.
  • We differentiated monohormonal densely or sparsely granulated GH-cell adenomas, monohormonal sparsely or very rarely densely granulated prolactin cell adenomas, monohormonal densely or sparsely ACTH-cell adenomas, monohormonal TSH-cell adenomas and FSH/LH cell adenomas from bihormonal adenomas of mammosomatotroph or GH/prolactin cell type or of the acidophil stem cell adenoma type.
  • These appear as subtypes of one entity deriving from the gonadotroph cell type.
  • Craniopharyngiomas are classified into adamantinous and papillary types, which are not only structurally but also clinically different.
  • [MeSH-minor] Adenoma / pathology. Adenoma / secretion. Diagnosis, Differential. Humans. Pituitary Hormones / secretion. Sella Turcica / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1981;54(3):257-60 [6167138.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1313-8; discussion 1318-9 [11126902.001]
  • [Cites] Pathol Res Pract. 1991 Jun;187(5):632-6 [1923959.001]
  • [Cites] Endocr Pathol. 1996 Spring;7(1):21-35 [12114677.001]
  • [Cites] Pathol Res Pract. 1988 Sep;183(5):592-5 [3237549.001]
  • [Cites] Pathologe. 1997 Nov;18(6):419-24 [9451729.001]
  • [Cites] Endocr Pathol. 1995 Summer;6(2):135-143 [12114649.001]
  • [Cites] Exp Clin Endocrinol. 1988 Aug;91(3):341-9 [3251773.001]
  • [Cites] Endocr Pathol. 2000 Autumn;11(3):215-227 [12114694.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 May;128(5):411-7 [8317187.001]
  • [Cites] Gen Diagn Pathol. 1995 Oct;141(2):81-92 [8548598.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(2):147-51 [11459086.001]
  • [Cites] Pituitary. 1999 May;1(3-4):213-20 [11081200.001]
  • [Cites] Arch Pathol Lab Med. 1986 Jan;110(1):72-5 [3510059.001]
  • [Cites] Pathol Res Pract. 1993 Nov;189(9):1044-51 [8302723.001]
  • [Cites] Pathologe. 2001 Sep;22(5):296-309 [11572110.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(4):417-31 [2426859.001]
  • [Cites] Neurosurgery. 1993 Nov;33(5):920-4; discussion 924-5 [8264895.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Apr;54(4):479-84 [11318783.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):677-83; discussion 683-4 [7596496.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;394(3):255-67 [6280372.001]
  • (PMID = 14513271.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Pituitary Hormones
  • [Number-of-references] 27
  •  go-up   go-down


43. Shimizu J, Matsumoto M, Yamazaki E, Yasue M: Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo); 2008 May;48(5):227-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration.
  • An 80-year-old male visited the hospital as an outpatient with a head injury sustained in a traffic accident.
  • Brain computed tomography incidentally revealed a left frontal lobe tumor measuring 5 cm in a diameter.
  • The patient had a history of taking chlormadinone acetate (a progesterone agonist) prescribed several years previously as treatment for benign prostatic hypertrophy.
  • The tumor was seen as an isointense lesion on T(1)-weighted magnetic resonance (MR) images with enhancement by gadolinium, and as a heterogeneously hyperintense mass on T(2)-weighted MR images.
  • The tentative diagnosis was left frontal meningioma attached to the sphenoid ridge or sphenoid plane.
  • The medication for benign prostatic hypertrophy was changed from chlormadinone acetate to naftopidil (an alpha-2-blocker) about 9 months after his first presentation.
  • Computed tomography and MR imaging performed at this time revealed remarkable regression of the tumor.
  • The signal intensity change with regression of the tumor on T(2)-weighted images was observed as a hypointense lesion.
  • Thus, we wish to emphasize that treatment of meningiomas, especially those diagnosed incidentally, must be based on a thorough consideration of any history of hormonal therapy with prostate disease.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Chlormadinone Acetate / administration & dosage. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Regression, Spontaneous
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Progesterone / agonists. Prostatic Hyperplasia / drug therapy

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0SY050L61N / Chlormadinone Acetate; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


44. Sasayama T, Nishihara M, Tanaka K, Mizukawa K, Ehara K, Kanomata N, Kohmura E: Two metachronous tumors induced by radiation therapy: case report and review of the literature. J Neurooncol; 2008 Jul;88(3):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two metachronous tumors induced by radiation therapy: case report and review of the literature.
  • Various radiation-induced tumors, including meningioma, glioma, and sarcoma, have been reported; however, metachronous intracranial double tumors induced by radiation therapy are extremely rare.
  • A 1-year-old boy had undergone tumor removal and craniospinal radiation therapy (30 Gy) for cerebellar medulloblastoma.
  • At 24 years old, parasagittal meningioma developed in the left parietal region and was totally removed.
  • Six years later, an infiltrative tumor was newly found in the right fronto-temporal white matter.
  • The patient underwent stereotactic biopsy, and the tumor was found to be an anaplastic astrocytoma.
  • As the patient had previously had craniospinal irradiation, no additional radiation therapy was delivered.
  • He underwent chemotherapy with temozolomide and the disease is now stable.
  • Since both secondary tumors were located within the area of previous radiation and the patient did not have any genetic disease predisposing him to tumors, radiation therapy was considered to be responsible for their tumorigenesis.
  • To our knowledge, this case is the fourth case of radiation-induced double CNS tumors arising after radiotherapy to be described in the literature.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasms, Radiation-Induced / pathology. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):390-7 [10958546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):161-81 [15674476.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):73-7 [16292489.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1002-13 [15200115.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):393-6 [9007876.001]
  • [Cites] Radiat Oncol. 2007 Jan 11;2:5 [17217530.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):143-6 [10729825.001]
  • [Cites] Childs Nerv Syst. 2006 Sep;22(9):1201-7 [16570196.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4091-5 [8508374.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] Neurol Res. 2007 Oct;29(7):723-6 [17553214.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):685-90 [7596497.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):763-70 [9810442.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):614-20 [10901233.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Cancer Lett. 1999 Jan 29;135(2):223-8 [10096432.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • [Cites] Neurosurgery. 1996 May;38(5):915-24; discussion 924-5 [8727816.001]
  • (PMID = 18373066.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Kargiotis O, Chetty C, Gogineni V, Gondi CS, Pulukuri SM, Kyritsis AP, Gujrati M, Klopfenstein JD, Dinh DH, Rao JS: uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Int J Oncol; 2008 Nov;33(5):937-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.
  • Meningioma is a well-known tumor of the central nervous system, and is treated by surgical resection and/or radiation.
  • Recently, ionizing radiation has been shown to enhance invasiveness of surviving tumor cells, and several proteolytic enzyme molecules, including urokinase plasminogen activator (uPA), seem to be upregulated after radiation. uPA and its receptor (uPAR) have been strongly implicated in tumor invasion, angiogenesis and progression.
  • Hence, the tumor-associated uPA-uPAR system is considered a potential target for cancer therapy.
  • In the present study, we show that radiation increases uPA levels in the IOMM-Lee meningioma cells, and subsequently, increases tumor invasion, migration and angiogenesis in vitro.
  • Further, a bicistronic plasmid construct with small interfering RNA (siRNA) against uPA and its receptor inhibited tumor invasion, migration and angiogenesis in radiation-treated IOMM-Lee cells.
  • In addition, siRNA against uPA and its receptor inhibited subcutaneous tumor growth in athymic nude mice in combination with radiation in a synergistic manner.
  • Thus, the specific targeting of proteases via RNA interference could augment the therapeutic effect of radiation and prevent the adverse effects resulting from tumor cells that receive sublethal doses of radiation within the tumor mass.

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Radiation induced meningioma.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] Med Res Rev. 2004 Jan;24(1):13-39 [14595671.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):13-8 [14729600.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11051-64 [14704150.001]
  • [Cites] Int J Cancer. 2004 May 20;110(1):125-33 [15054877.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23151-7 [15047712.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Jun;4(4):327-36 [15180498.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Biol Chem. 1992 Oct 5;267(28):20493-6 [1328201.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:1-12 [1339240.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32380-8 [7528215.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9 [7835780.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):9709-16 [7730348.001]
  • [Cites] Science. 1996 Sep 13;273(5281):1551-5 [8703217.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Oncology. 2004;67(3-4):310-9 [15557793.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):676-81 [15841311.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Eur J Surg Oncol. 2005 Oct;31(8):869-74 [16081236.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Mol Cancer Ther. 2005 Nov;4(11):1717-28 [16275993.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] Int J Oncol. 2006 Apr;28(4):831-9 [16525631.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):227-37 [16200346.001]
  • [Cites] Int J Oncol. 2006 Jun;28(6):1353-60 [16685436.001]
  • [Cites] Neurosurg Clin N Am. 2006 Apr;17(2):111-20, vi [16793503.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8511-9 [16951163.001]
  • [Cites] Int J Oncol. 2006 Dec;29(6):1525-31 [17088992.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):789-801 [17363476.001]
  • [Cites] Int J Oncol. 2007 Jul;31(1):19-27 [17549401.001]
  • [Cites] J Clin Neurosci. 2007 Aug;14(8):747-53 [17499508.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2884-90 [10537357.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1367-74 [11245436.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2744-50 [11289157.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):1087-93 [11309361.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2519-26 [11489835.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1359-64 [11818541.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12479-85 [11805108.001]
  • [Cites] Biol Chem. 2002 Jan;383(1):5-19 [11928822.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):392-400 [12545160.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1467-71 [12883725.001]
  • (PMID = 18949356.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS061835; United States / NINDS NIH HHS / NS / NS47699; United States / NINDS NIH HHS / NS / R01 NS057529; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / R01 CA116708-03; United States / NCI NIH HHS / CA / R01 CA095058-04; United States / NINDS NIH HHS / NS / R01 NS057529-02; United States / NINDS NIH HHS / NS / NS57529; United States / NINDS NIH HHS / NS / R01 NS061835-01; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA116708-03; United States / NCI NIH HHS / CA / CA075557-10; United States / NCI NIH HHS / CA / CA 92393; United States / NINDS NIH HHS / NS / NS061835-01; United States / NCI NIH HHS / CA / CA 95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NINDS NIH HHS / NS / NS057529-02; United States / NCI NIH HHS / CA / CA092393-04; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708; United States / NCI NIH HHS / CA / R01 CA092393-04; United States / NINDS NIH HHS / NS / R01 NS047699-04A2; United States / NINDS NIH HHS / NS / NS047699-04A2; United States / NCI NIH HHS / CA / CA095058-04; United States / NINDS NIH HHS / NS / NS61835; United States / NCI NIH HHS / CA / R01 CA075557-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; 0 / Receptors, Urokinase Plasminogen Activator; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS66725; NLM/ PMC2575644
  •  go-up   go-down


46. Sinha S, Bastin ME, Wardlaw JM, Armitage PA, Whittle IR: Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J Neurol Neurosurg Psychiatry; 2004 Nov;75(11):1632-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study.
  • OBJECTIVES: Glucocorticoids (dexamethasone) are thought to reduce peritumoural brain oedema by decreasing the permeability of neoplastic capillaries and/or enhancing the clearance of extracellular water.
  • Diffusion tensor magnetic resonance imaging (DT-MRI) was used to measure the water diffusion parameters of oedematous and normal brain in a group of patients with intracranial tumours before and after steroid treatment.
  • METHODS: Fifteen patients with intracranial tumours (seven with high-grade glioma, four with metastatic carcinoma and four with meningioma) were examined before and 48-72 h after dexamethasone treatment (16 mg/day).
  • The mean diffusivity (<D>) and fractional anisotropy (FA) were measured for oedematous brain and apparently normal contralateral white matter before and after steroid therapy.
  • RESULTS: In all three patient groups there was a significant decrease in <D> of oedematous brain after steroid treatment (p<0.01).
  • There was no significant change in FA of oedematous brain after treatment in any of the three groups.
  • There was also no significant change in either <D> or FA of apparently normal contralateral white matter after treatment.
  • CONCLUSION: These data indicate that dexamethasone produces a localised reduction in the magnitude of extracellular water molecule mobility, and hence water content, in peritumoural oedematous brain.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Brain Edema / drug therapy. Dexamethasone / therapeutic use. Diffusion Magnetic Resonance Imaging. Glioblastoma / drug therapy. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Anisotropy. Brain / drug effects. Brain / pathology. Capillary Permeability / drug effects. Extracellular Fluid / drug effects. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15489404.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 7S5I7G3JQL / Dexamethasone
  • [Other-IDs] NLM/ PMC1738808
  •  go-up   go-down


47. Cardous-Ubbink MC, Heinen RC, Bakker PJ, van den Berg H, Oldenburger F, Caron HN, Voûte PA, van Leeuwen FE: Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer; 2007 Jan;43(2):351-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median follow-up time was 16.8 years.
  • New observations were the strongly increased risks of meningiomas (SIR=40) and basal cell carcinomas (SIR=9).
  • Patients whose treatment involved radiotherapy had a 2-fold increased second cancer risk compared to patients with chemotherapy alone.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17141498.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Lacoste-Collin L, Roux FE, Gomez-Brouchet A, Despeyroux ML, Uro-Coste E, Coindre JM, Delisle MB: Inflammatory myofibroblastic tumor: a spinal case with aggressive clinical course and ALK overexpression. Case report. J Neurosurg; 2003 Mar;98(2 Suppl):218-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor: a spinal case with aggressive clinical course and ALK overexpression. Case report.
  • The authors report on a case of spinal inflammatory myofibroblastic tumor (IMT) in a 22-year-oldwoman.
  • Neuroradiological features of this intradural extramedullary mass were suggestive of a meningioma or neurinoma.
  • The lesion was easily resected following a T-9 laminectomy.
  • This led to the diagnosis of IMT.
  • The patient's postoperative course was complicated by a multifocal local recurrence requiring a second surgery, which was followed by radio- and chemotherapy.
  • This has been recently reported in this tumor typein other locations.
  • [MeSH-major] Fibroblasts / pathology. Muscle, Smooth / pathology. Protein-Tyrosine Kinases / metabolism. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / enzymology
  • [MeSH-minor] Adult. Female. Humans. Inflammation / diagnosis. Inflammation / pathology. Inflammation / physiopathology. Magnetic Resonance Imaging. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12650409.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


49. Evans DG: Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis; 2009;4:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2 (NF2): a clinical and molecular review.
  • Neurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the development of multiple schwannomas and meningiomas.
  • Nausea, vomiting or true vertigo are rare symptoms, except in late-stage disease.
  • The other main tumours are schwannomas of the other cranial, spinal and peripheral nerves; meningiomas both intracranial (including optic nerve meningiomas) and intraspinal, and some low-grade central nervous system malignancies (ependymomas).
  • Neurofibromatosis type 2 is a dominantly inherited tumour predisposition syndrome caused by mutations in the NF2 gene on chromosome 22.
  • More than 50% of patients represent new mutations and as many as one-third are mosaic for the underlying disease-causing mutation.
  • Although truncating mutations (nonsense and frameshifts) are the most frequent germline event and cause the most severe disease, single and multiple exon deletions are common.
  • A strategy for detection of the latter is vital for a sensitive analysis.
  • Diagnosis is based on clinical and neuroimaging studies.
  • Prenatal diagnosis and pre-implantation genetic diagnosis is possible.
  • The main differential diagnosis of NF2 is schwannomatosis.
  • Surgery remains the focus of current management although watchful waiting with careful surveillance and occasionally radiation treatment have a role.
  • Prognosis is adversely affected by early age at onset, a higher number of meningiomas and having a truncating mutation.
  • In the future, the development of tailored drug therapies aimed at the genetic level are likely to provide huge improvements for this devastating condition.


50. Johannesen TB, Lien HH, Hole KH, Lote K: Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy. Radiother Oncol; 2003 Nov;69(2):169-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy.
  • BACKGROUND AND PURPOSE: Late adverse effects of therapeutic brain radiotherapy (RT) may develop after long latency periods and our objective was to assess long-term brain tumour survivors following RT to large partial brain volumes.
  • MATERIALS AND METHODS: Assessment of MRI, SOMA/LENT score, quality of life and neuroendocrine function was performed in 33 adult brain tumour patients 6-25 years following RT.
  • Fraction dose was 1.8 Gy to a median total dose of 54 Gy (range: 45.0-59.4 Gy).
  • Patients treated with intra-arterial chemotherapy and patients at higher age at follow-up had significantly more grade 3 changes.
  • Two cases of meningioma were found at 16 and 22 years after RT.
  • CONCLUSIONS: External radiotherapy to the brain at a standard fractionation regime will cause varying degrees of late neurotoxicity and/or neuroendocrine disturbances in most patients.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radiation Injuries

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14643954.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


51. Andersson U, Malmer B, Bergenheim AT, Brännström T, Henriksson R: Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol; 2004 Jan-Feb;23(1):21-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity in the expression of markers for drug resistance in brain tumors.
  • Brain tumors, in general, display a multidrug-resistant phenotype.
  • This study evaluated the immunohistochemical expression and distribution of P-glycoprotein (Pgp), multidrug resistance protein (MRP1), lung resistance protein (LRP) and O6 methylguanine-DNA methyltransferase (MGMT) in low- and high-grade astrocytoma, oligodendroglioma and in different subgroups of meningioma.
  • The results revealed a marked heterogeneity in the expression and distribution among the analyzed tumors.
  • In astrocytoma and oligodendroglioma, Pgp and MRP1 were observed in the capillary endothelium and in scattered tumor cells, whereas LRP occurred only in tumor cells.
  • In meningioma, a heterogeneous expression of Pgp, MRP1, LRP and MGMT was seen with the most prominent staining localized to the capillary endothelium.
  • Pgp was significantly more often overexpressed (p < 0.05) in transitional compared to meningothelial meningioma.
  • The marked heterogeneity in the expression suggests that analysis of these factors can be of importance in the selection of individualized chemotherapy, regardless of tumor type.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioma / metabolism. Meningioma / metabolism. Neoplasm Proteins / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain / metabolism. Child. Child, Preschool. Drug Resistance, Neoplasm / physiology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14986930.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


52. Salvati M, Caroli E, Raco A, Giangaspero F, Delfini R, Ferrante L: Gliosarcomas: analysis of 11 cases do two subtypes exist? J Neurooncol; 2005 Aug;74(1):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study is to examine clinical, radiological, surgical and therapeutic aspects of 11 patients with gliosarcoma.
  • Four patients received whole brain radiotherapy with (60)Co, five underwent radiotherapy with LINAC extended 2 cm beyond the edema margins.
  • One patient refused any additional treatment after surgery and one patient was not treated postoperatively for poor clinical conditions (KPS 40).
  • Chemotherapy (temozolomide) was administered to four patients.
  • Four patients had a prevalence of sarcomatous component that corresponded to surgical and radiological aspects similar to meningioma while six patients showed a prevalence of gliomatous component and radiological and surgical aspects similar to those of glioblastomas.
  • Patients with prevalent sarcomatous component showed median survival time more prolonged than patients with prevalent gliomatous component (71 +/- 6 weeks vs. 63 +/- 6; P=0.0417).
  • Moreover, the survival rate differed in relation to the therapy: patients treated with multimodality therapy (surgery, radiotherapy and chemotherapy) had a longer survival time than patients treated in single or bimodality.
  • Despite prognosis of gliosarcomas remains poor, a multidisciplinary approach (surgery, radiotherapy and chemotherapy) seems to be associated with slight more prolonged survival times.
  • [MeSH-major] Brain Neoplasms / pathology. Gliosarcoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S194-8 [8453697.001]
  • [Cites] J Neurosurg. 1976 Oct;45(4):398-408 [956876.001]
  • [Cites] Cancer. 1969 Aug;24(2):270-6 [4307749.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2910-8 [7773942.001]
  • [Cites] Neuropathol Appl Neurobiol. 1991 Jun;17(3):177-87 [1653908.001]
  • [Cites] Indian J Cancer. 1994 Jun;31(2):118-23 [7927444.001]
  • [Cites] Mod Pathol. 1990 Jan;3(1):19-24 [2155418.001]
  • [Cites] J Comput Assist Tomogr. 1996 Sep-Oct;20(5):719-23 [8797900.001]
  • [Cites] Neurosurg Rev. 1996;19(2):93-6 [8837107.001]
  • [Cites] Cancer. 1991 May 1;67(9):2342-9 [1849447.001]
  • [Cites] Cancer. 1958 Mar-Apr;11(2):264-77 [13511345.001]
  • [Cites] Acta Neuropathol. 1984;63(2):108-16 [6428154.001]
  • [Cites] Acta Neuropathol. 1990;81(2):178-88 [2082657.001]
  • [Cites] Am J Pathol. 1955 Jul-Aug;31(4):633-53 [14388124.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):57-64 [11578729.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):410-2 [10448291.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):554-6 [2058514.001]
  • [Cites] Br J Neurosurg. 1995 Apr;9(2):171-8 [7632363.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):413-8 [4047352.001]
  • [Cites] Prog Exp Tumor Res. 1985;29:1-11 [4070625.001]
  • [Cites] Cancer. 1988 Jul 1;62(1):58-66 [3289727.001]
  • [Cites] Neurosurgery. 1990 Feb;26(2):261-7 [2308674.001]
  • [Cites] Acta Neuropathol. 1985;67(3-4):201-10 [4050334.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Sep;55(9):973-81 [8800093.001]
  • [Cites] J Neurosurg. 1998 Sep;89(3):425-30 [9724117.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):147-55 [3791141.001]
  • [Cites] AJNR Am J Neuroradiol. 1985 Jul-Aug;6(4):527-31 [3927668.001]
  • [Cites] Neurol Med Chir (Tokyo). 1989 Mar;29(3):223-9 [2477727.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):425-32 [10666371.001]
  • [Cites] J Neuropathol Exp Neurol. 1992 Sep;51(5):493-8 [1381414.001]
  • [Cites] Indian J Med Res. 1997 Sep;106:229-35 [9378529.001]
  • [Cites] Cancer. 1958 Sep-Oct;11(5):888-94 [13585341.001]
  • [Cites] Acta Oncol. 1997;36(7):771-4 [9490099.001]
  • [Cites] Acta Neuropathol. 1994;88(5):420-5 [7847070.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Sep;54(5):651-6 [7666053.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(1):91-5 [10664381.001]
  • (PMID = 16078109.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Hatta R, Nambu Y, Suzuki S, Tachi Y, Oikawa T, Nakagawa K, Tuchihara K, Tobe T, Osanai K, Toga H, Takahashi K, Ohya N: [A case of atypical pulmonary carcinoid accompanying skin metastasis]. Nihon Kokyuki Gakkai Zasshi; 2004 Apr;42(4):357-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 73-year-old woman underwent cranial surgery in 1999 after receiving a diagnosis of suspected malignant meningioma.
  • She began complaining of headache 2 years postoperatively, and around the same time, she noticed a painful skin tumor.
  • The skin tumor was diagnosed by skin biopsy as an atypical metastatic carcinoid tumor.
  • Pulmonary, skin and bone biopsy samples exhibited the same pathological findings as those of the atypical pulmonary carcinoid tumor.
  • EP therapy (etoposide + carboplatin) and CAV therapy (cyclophosphamide + doxorubicin + vincristin) were administered, but there was no clinical response.
  • The patient is currently doing well without chemotherapy and is being followed by the Outpatient Department.
  • [MeSH-major] Carcinoid Tumor / pathology. Carcinoid Tumor / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114855.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


54. Dagcinar A, Bayrakli F, Yapicier O, Ozek M: Primary meningeal osteosarcoma of the brain during childhood. Case report. J Neurosurg Pediatr; 2008 Apr;1(4):325-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary meningeal osteosarcoma of the brain during childhood. Case report.
  • Primary meningeal osteosarcomas are rare tumors, with only 19 reported cases in the literature; only 4 of these, including the present case, are in pediatric patients.
  • In this report, the authors present the case of an 8-year-old boy with a history of generalized tonic-clonic seizures who was found to harbor a meningeal osteosarcoma within the sylvian fissure.
  • Initial working diagnoses included meningioma and glioma.
  • After tumor enlargement and progressive symptoms, the patient underwent a large frontotemporal craniotomy and complete resection of the lesion, which recurred 6 and 12 months after the initial surgery and was surgically treated after each recurrence.
  • The rarity of primary meningeal osteosarcomas can make their diagnosis difficult, and histopathological evaluation is mandatory for diagnosis.
  • Because of their fast progression, they must be treated aggressively by means of surgery, chemotherapy, and radiotherapy.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Osteosarcoma / surgery
  • [MeSH-minor] Cerebral Aqueduct. Child. Craniotomy. Humans. Male. Neoplasm Recurrence, Local


55. Tamer G, Kartal I, Aral F: Pituitary infiltration by non-Hodgkin's lymphoma: a case report. J Med Case Rep; 2009;3:9293
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Pituitary adenomas represent the most frequently observed type of sellar masses; however, the presence of a rapidly growing sellar tumor, diabetes insipidus, ophthalmoplegia and headaches in an older patient strongly suggests metastasis to the pituitary.
  • Paranasal sinus computed tomography scanning and magnetic resonance imaging of the thorax and abdomen were performed.
  • Since magnetic resonance imaging did not reveal any abnormality, after paranasal sinus computed tomography was performed, we concluded that the primary lymphoma originated from the sphenoid sinus and infiltrated the pituitary.
  • Chemotherapy and radiotherapy to the sellar area were planned, but the patient died and her family did not permit an autopsy.
  • CONCLUSION: Lymphoma infiltration to the pituitary is difficult to differentiate from pituitary adenoma, meningioma and other sellar lesions.
  • To plan the treatment of lymphoma infiltration of the pituitary gland, it must be differentiated from other sellar lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2002 Mar;23(3):364-7 [11901000.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 May;23(5):838-40 [12006288.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):574-80 [14764764.001]
  • [Cites] Pituitary. 2005;8(2):139-46 [16379034.001]
  • [Cites] J Neurosurg. 2007 Sep;107(3):660-5 [17886569.001]
  • [Cites] Int J Clin Pract. 1998 Oct;52(7):513-4 [10622097.001]
  • [Cites] Neth J Med. 1987 Apr;30(3-4):135-43 [3600898.001]
  • [Cites] Intern Med. 1994 Dec;33(12):795-8 [7718964.001]
  • [Cites] J Neurooncol. 1993 Aug;17(2):155-8 [8145058.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):69-73 [9647174.001]
  • [Cites] Haematol Blood Transfus. 1990;33:571-6 [2323657.001]
  • (PMID = 20062782.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803816
  •  go-up   go-down


56. Yamamoto T, Nakai K, Matsumura A: Boron neutron capture therapy for glioblastoma. Cancer Lett; 2008 Apr 18;262(2):143-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for glioblastoma.
  • Boron neutron capture therapy (BNCT) theoretically allows the preferential destruction of tumor cells while sparing the normal tissue, even if the cells have microscopically spread to the surrounding normal brain.
  • The tumor cell-selective irradiation used in this method is dependent on the nuclear reaction between the stable isotope of boron ((10)B) and thermal neutrons, which release alpha and (7)Li particles within a limited path length (-9 microm) through the boron neutron capture reaction, (10)B(n,alpha)(7)Li.
  • Recent clinical studies of BNCT have focused on high-grade glioma and cutaneous melanoma; however, cerebral metastasis of melanoma, anaplastic meningioma, head and neck tumor, and lung and liver metastasis have been investigated as potential candidates for BNCT.
  • Improved tumor-targeting boron compounds and optimized administration methods, improved boron drug delivery systems, development of a hospital-based neutron source, and/or other combination modalities will enhance the therapeutic effectiveness of BNCT in the future.
  • [MeSH-major] Boron Neutron Capture Therapy. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Boron / therapeutic use. Clinical Trials as Topic. Forecasting. Humans. Photons / therapeutic use. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. BORON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313207.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] N9E3X5056Q / Boron
  • [Number-of-references] 77
  •  go-up   go-down


57. Weller M: [Chemotherapy for brain tumors in adult patients]. Nervenarzt; 2008 Feb;79(2):231-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for brain tumors in adult patients].
  • [Transliterated title] Chemotherapie von Hirntumoren bei Erwachsenen.
  • Chemotherapy has become a third major treatment option for patients with brain tumors, in addition to surgery and radiotherapy.
  • The role of chemotherapy in the treatment of gliomas is no longer limited to recurrent disease.
  • Several ongoing trials seek to define the role of chemotherapy in the primary care of other gliomas.
  • Outside such clinical trials chemotherapy is used in addition to radiotherapy, e.g., in anaplastic astrocytoma, medulloblastoma or germ cell tumors, or as an alternative to radiotherapy, e.g., in anaplastic oligodendroglial tumors or low-grade gliomas.
  • In contrast, there is no established role for chemotherapy in other tumors such as ependymomas, meningiomas or neurinomas.
  • Primary cerebral lymphomas are probably the only brain tumors which can be cured by chemotherapy alone and only by chemotherapy.
  • The chemotherapy of brain metastases follows the recommendations for the respective primary tumors.
  • Leptomeningeal metastases are treated by radiotherapy or systemic or intrathecal chemotherapy depending on their pattern of growth.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Genetic Markers / genetics. Humans. Prognosis. Promoter Regions, Genetic / genetics. Topotecan / adverse effects. Topotecan / therapeutic use. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2005 Feb;71(3):271-6 [15735916.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):44-55; discussion 55-6 [12182434.001]
  • [Cites] Neurologist. 2006 Jul;12(4):179-87 [16832237.001]
  • [Cites] Curr Treat Options Neurol. 2006 Jul;8(4):346-57 [16942677.001]
  • [Cites] Nervenarzt. 2003 Dec;74(12):1139-49 [14994756.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] J Neurol. 2005 Mar;252(3):291-9 [16189725.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):143-8 [15912507.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 [16482400.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Dec;20(6):1287-95 [17113463.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18253773.001).
  • [ISSN] 0028-2804
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 7M7YKX2N15 / Topotecan; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
  •  go-up   go-down


58. Wessling H, Simosono CL, Escosa-Bagé M, de Las Heras-Echeverría P: Anton's syndrome due to a giant anterior fossa meningioma. The problem of routine use of advanced diagnostic imaging in psychiatric care. Acta Neurochir (Wien); 2006 Jun;148(6):673-5; discussion 675
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anton's syndrome due to a giant anterior fossa meningioma. The problem of routine use of advanced diagnostic imaging in psychiatric care.
  • We present a case of blindness and Anton's syndrome in a psychiatric patient with late diagnosis of a giant frontal meningioma.
  • We conclude that MR or CT scan is indicated in psychiatric in-patients who fail to improve with standard psychiatric treatment.
  • [MeSH-major] Blindness, Cortical / etiology. Cranial Fossa, Anterior / pathology. Diagnostic Errors. Intellectual Disability / etiology. Meningeal Neoplasms / complications. Meningioma / complications
  • [MeSH-minor] Adult. Corpus Callosum / pathology. Corpus Callosum / surgery. Decompression, Surgical. Disease Progression. Epilepsy / etiology. Epilepsy / physiopathology. Frontal Lobe / pathology. Frontal Lobe / surgery. Hospitals, Psychiatric / standards. Humans. Male. Mental Competency. Mental Disorders / drug therapy. Mental Disorders / etiology. Mental Disorders / physiopathology. Neurosurgical Procedures. Optic Nerve / pathology. Schizophrenia, Disorganized / diagnosis. Schizophrenia, Disorganized / etiology. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Anton's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598409.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


59. Lee KL, Terris MK: Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma. Urology; 2003 Aug;62(2):351
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma.
  • The relative contraindication of hormonal therapy for patients with prostate cancer and a history of meningioma has not been widely emphasized.
  • Using immunohistochemistry to determine the presence of hormone receptors in meningioma specimens proved potentially valuable in 2 patients with biochemical recurrence after prostatectomy who were being considered for androgen deprivation therapy.
  • These cases also highlight the need for caution against assuming that skull-based intracranial growths in patients receiving hormonal therapy for prostate cancer are metastatic lesions rather than hormonally induced primary tumors.
  • [MeSH-major] Gonadotropin-Releasing Hormone / adverse effects. Gonadotropin-Releasing Hormone / agonists. Meningeal Neoplasms / chemically induced. Meningioma / chemically induced
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / chemically induced. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / chemically induced. Prostatectomy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12893358.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


60. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergün S, Westphal M: Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery; 2000 Apr;46(4):938-47; discussion 947-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.
  • OBJECTIVE: Angiogenesis is mediated by a number of different growth factors and appears vital for tumor growth.
  • The understanding of angiogenic mechanisms could offer new therapeutic perspectives; in this context, the role of four potentially angiogenic growth factors was analyzed in a large series of meningiomas of different grades.
  • METHODS: Vascular endothelial growth factor (VEGF), placenta growth factor, hepatocyte growth factor/scatter factor, and basic fibroblast growth factor were quantified in 69 tumors by enzyme-linked immunosorbent assay.
  • Microvessel density and proliferative activity were determined on paraffin sections, and clinical tumor invasiveness was rated.
  • RESULTS: Tumors included 40 benign (World Health Organization [WHO] Grade I), 21 atypical (WHO Grade II), and 8 anaplastic/malignant (WHO Grade III) meningiomas.
  • We found a correlation between meningioma grade and VEGF content (r = 0.37, P = 0.002), which was 2-fold higher in atypical than in benign meningiomas (P = 0.022) and 10-fold higher in malignant than in benign meningiomas (P = 0.025).
  • Among different subtypes of Grade I meningiomas, VEGF levels were 10-fold higher in meningothelial than in fibrous meningiomas (P = 0.015).
  • None of the other three factors investigated showed any association with tumor grade, microvessel density, or invasiveness, and VEGF also did not correlate with vascularity or invasiveness.
  • Endothelial chemotaxis and capillary-like tube formation in vitro were induced by meningioma extracts and were most effectively blocked by co-addition of antibodies against basic fibroblast growth factor, followed by anti-VEGF, whereas anti-hepatocyte growth factor/scatter factor was not effective.
  • The chemotactic activity of meningioma extracts on endothelial cells correlated with their VEGF content (r = 0.6, P = 0.003).
  • CONCLUSION: Meningiomas do not show an angiogenic switch involving VEGF and/or hepatocyte growth factor/scatter factor, as has previously been found in gliomas.
  • Nevertheless, the biological activity of VEGF and basic fibroblast growth factor in meningiomas suggests that both are potential targets for antiangiogenic therapy in meningiomas of all WHO grades.
  • [MeSH-major] Endothelial Growth Factors / metabolism. Fibroblast Growth Factor 2 / metabolism. Hepatocyte Growth Factor / metabolism. Lymphokines / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Pregnancy Proteins / metabolism
  • [MeSH-minor] Chemotaxis. Endothelium, Vascular / drug effects. Endothelium, Vascular / pathology. Endothelium, Vascular / physiopathology. Humans. Neoplasm Invasiveness. Neovascularization, Pathologic / chemically induced. Neovascularization, Pathologic / pathology. Tissue Extracts / pharmacology. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10764269.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Pregnancy Proteins; 0 / Tissue Extracts; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; 144589-93-5 / placenta growth factor; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


61. Varma AK, Muller PJ: Cranial neuropathies after intracranial Photofrin-photodynamic therapy for malignant supratentorial gliomas-a report on 3 cases. Surg Neurol; 2008 Aug;70(2):190-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial neuropathies after intracranial Photofrin-photodynamic therapy for malignant supratentorial gliomas-a report on 3 cases.
  • BACKGROUND: In an RCT of PDT in the treatment of malignant gliomas, 3 patients developed cranial neuropathies after photoillumination.
  • We are aware of no previous reports on cranial neuropathy after intracranial PDT.
  • METHODS: In a cohort of 80 patients, there were 41 men and 39 women; 47 were newly diagnosed and 33 had recurrent tumors.
  • All patients underwent surgical tumor extirpation.
  • There were 77 malignant gliomas, 2 meningiomas, and 1 metastatic tumor.
  • The tumor locations were as follows: 39 frontal, 25 temporal, 12 parietal, and 4 occipital.
  • Of the 25 patients with temporal lobe tumors, 18 received PDT.
  • RESULTS: Three of the 18 patients with temporal lobe tumors developed cranial neuropathies after PDT.
  • This complication was not seen in any other patient with tumors in the frontal, parietal, or occipital regions, or patients with temporal lobe tumors who did not receive PDT.
  • The first patient developed seventh nerve paresis and hypoesthesia in fifth nerve distribution, which resolved only partially.
  • The second patient developed a seventh nerve paresis that resolved completely.
  • The third patient developed transient neuralgic pain in the trigeminal nerve distribution.
  • [MeSH-major] Cranial Nerve Diseases / chemically induced. Dihematoporphyrin Ether / adverse effects. Glioma / drug therapy. Peripheral Nervous System Diseases / chemically induced. Photochemotherapy / adverse effects. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / adverse effects. Cranial Fossa, Middle / pathology. Facial Nerve / anatomy & histology. Facial Nerve / drug effects. Facial Nerve / physiopathology. Facial Nerve Diseases / chemically induced. Facial Nerve Diseases / metabolism. Facial Nerve Diseases / physiopathology. Female. Humans. Light / adverse effects. Male. Middle Aged. Photic Stimulation / adverse effects. Preoperative Care / standards. Temporal Lobe / pathology. Temporal Lobe / physiopathology. Trigeminal Nerve / anatomy & histology. Trigeminal Nerve / drug effects. Trigeminal Nerve / physiopathology. Trigeminal Nerve Diseases / chemically induced. Trigeminal Nerve Diseases / metabolism. Trigeminal Nerve Diseases / physiopathology

  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976702.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


62. Hentschel S, Toyota B: Intracranial malignant glioma presenting as subarachnoid hemorrhage. Can J Neurol Sci; 2003 Feb;30(1):63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial malignant glioma presenting as subarachnoid hemorrhage.
  • Cerebral neoplasms are clearly on this list but are most commonly meningiomas or metastatic lesions.
  • This article details a case of a neoplasm that presented exclusively with SAH.
  • CLINICAL PRESENTATION: A 40-year-old male presented with a SAH with normal cerebral angiography.
  • INTERVENTION: Craniotomy and resection of the lesion established a diagnosis of a malignant oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Oligodendroglioma / diagnosis. Subarachnoid Hemorrhage / etiology
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Cerebral Angiography. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Seizures / drug therapy. Seizures / etiology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12619787.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


63. McDonnell JJ, Kalbko K, Keating JH, Sato AF, Faissler D: Multiple meningiomas in three dogs. J Am Anim Hosp Assoc; 2007 Jul-Aug;43(4):201-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple meningiomas in three dogs.
  • Three dogs with seizures were diagnosed with multiple intracranial meningiomas.
  • Treatment consisted of surgery and radiation (n=2) or chemotherapy (n=1).
  • In all three cases, the masses were two distinct tumors as determined by imaging, surgery, or necropsy.
  • In two dogs, the meningiomas had the same histological pattern, while in one dog the histological subtypes were different.
  • [MeSH-major] Dog Diseases / diagnosis. Meningeal Neoplasms / veterinary. Meningioma / veterinary. Seizures / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Dogs. Female. Male

  • MedlinePlus Health Information. consumer health - Seizures.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615400.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Ragel BT, Couldwell WT, Wurster RD, Jensen RL: Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg Focus; 2007;23(4):E10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas.
  • In this article, the authors review the research supporting the use of calcium channel antagonists (CCAs) in the treatment of recurrent or unresectable meningiomas.
  • Calcium channel antagonists (for example, diltiazem and verapamil) are known to augment the effects of chemotherapy drugs (for example, vincristine) in multiple cancers.
  • The authors' initial work in this field was based on the then-emerging data that meningiomas are receptor positive for growth factor receptors (for example, platelet-derived growth factor [PDGF]), which are known to trigger calcium-dependent secondary messenger pathways.
  • In addition, diltiazem- and verapamil-treated meningiomas are less vascular and smaller, with decreased cell proliferation and increased apoptosis.
  • The use of CCAs is attractive as an adjunct treatment for unresectable or recurrent meningiomas because they are safe drugs with well-known side effect profiles that lend themselves to long-term chronic therapy.
  • [MeSH-major] Calcium Channel Blockers / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cell Proliferation / drug effects. Drug Therapy, Combination. Humans. Receptors, Growth Factor / drug effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961034.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Calcium Channel Blockers; 0 / Receptors, Growth Factor
  • [Number-of-references] 3
  •  go-up   go-down


65. Cage TA, Lamborn KR, Ware ML, Frankfurt A, Chakalian L, Berger MS, McDermott MW: Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas. J Neurooncol; 2009 May;93(1):151-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas.
  • Patients with brain tumors including intracranial meningiomas are at increased risk for developing deep vein thrombosis (DVTs) and suffering thromboembolic events (VTEs).
  • Many surgeons are concerned that early use of low dose enoxaparin may increase the risk of intracranial hemorrhage which outweighs the benefit of DVT/VTE reduction.
  • We aimed to address concerns around the use of enoxaparin after meningioma resection in the development of postoperative intracranial hemorrhages and DVT/VTEs.
  • This is a retrospective review of 86 patients with intracranial meningiomas who underwent craniectomy and surgical resection of the mass, treated by one attending surgeon at UCSF Medical Center between 2000 and 2005.
  • Within 48 h after surgery patients treated 2003-2005 routinely received enoxaparin therapy unless there was documented intracranial hemorrhage, lumbar subarachnoid drain, enoxaparin hypersensitivity, or thrombocytopenia (n = 24).
  • These were compared to a cohort treated 2000-2002 who did not receive the drug (n = 62).
  • The groups were similar in tumor and surgical characteristics.
  • Enoxaparin therapy did not increase the incidence of intracranial hemorrhage following surgical meningioma resection and the incidence of DVTs/VTEs was 0% (n = 0) versus 4.8% (n = 3) in the non-enoxaparin group.
  • In this retrospective study, postoperative administration of enoxaparin following meningioma resection does not increase the risk of intracranial hematoma though enoxaparin administration may slightly decrease the incidence of post-surgical thromboembolic events.
  • [MeSH-major] Anticoagulants / therapeutic use. Enoxaparin / therapeutic use. Meningeal Neoplasms / complications. Meningioma / complications. Postoperative Complications / prevention & control. Thrombosis / prevention & control
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Incidence. Intracranial Hemorrhages / epidemiology. Male. Middle Aged. Neurosurgical Procedures. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1977 Jul;47(1):27-30 [864504.001]
  • [Cites] Surg Neurol. 2002 Apr;57(4):241-51; discussion 251-2 [12173391.001]
  • [Cites] Acta Neurochir (Wien). 1986;80(3-4):83-9 [2424279.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1310-8 [16525187.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Neurol Res. 2004 Jan;26(1):61-6 [14977059.001]
  • [Cites] Neurosurgery. 2003 Nov;53(5):1028-34; discussion 1034-5 [14580268.001]
  • [Cites] Thromb Haemost. 1996 Feb;75(2):233-8 [8815566.001]
  • [Cites] Surg Neurol. 2007 Oct;68(4):407-11; discussion 411 [17586023.001]
  • [Cites] Oncol Nurs Forum. 2007 Jul;34(4):777-82 [17723979.001]
  • [Cites] Chest. 2002 Dec;122(6):1933-7 [12475829.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1074-81 [9802851.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):830-2; discussion 832-3 [1614582.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):300-5 [17154163.001]
  • [Cites] JAMA. 2005 Feb 9;293(6):715-22 [15701913.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):378-81 [681999.001]
  • [Cites] J Neurosurg. 2001 Jun;94(6):918-21 [11409520.001]
  • [Cites] Acta Neurochir (Wien). 1991;109(3-4):93-7 [1858538.001]
  • [Cites] J Neurol. 1975 Jul 2;209(3):217-24 [51062.001]
  • [Cites] N Engl J Med. 1998 Jul 9;339(2):80-5 [9654538.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):299-307 [11981275.001]
  • (PMID = 19430892.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Enoxaparin
  •  go-up   go-down


66. Tong-tong W, Li-juan B, Zhi L, Yang L, Bo-ning L, Quan H: Clear cell meningioma with anaplastic features: case report and review of literature. Pathol Res Pract; 2010 May 15;206(5):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell meningioma with anaplastic features: case report and review of literature.
  • Clear cell meningioma (CCM) is an uncommon variant of meningioma, corresponding to WHO grade II.
  • We present two cases of CCMs with anaplastic features in the intracranial and intraspinal region.
  • The first case is a 65-year-old male who gradually developed changes in behavior over a period of 1 year.
  • The second case is a 35-year-old female who presented with a 7-month history of posterior cervicothoracic pain and dysuria for 1 week.
  • Magnetic resonance imaging revealed an intracranial lesion in the right frontal lobe in the male patient, and an intradural extramedullary lesion at C7 in the female patient.
  • On histological examination, both tumors partly exhibited unusual anaplastic appearances with nuclear pleomorphism, high mitotic activity and necrosis, distinct from classical CCMs.
  • Tumor cells were immunoreactive to epithelial membrane antigen (EMA) and vimentin, with a high MIB-1 index up to 40%.
  • The male patient was found to have developed local recurrence and lateral ventricle metastasis 3 months after surgery.
  • A diagnosis of CCM with anaplastic features was made (WHO grade III).
  • Based on its aggressive behavior, we recommend postoperative adjuvant radiotherapy or chemotherapy even if total excision of the tumor has been performed, and MRI scans every 3-6 months during the first period of follow-up.
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Anaplasia / pathology. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier GmbH. All rights reserved.
  • (PMID = 19857933.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. Evans DG: Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med; 2009 Sep;11(9):599-610
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II].
  • Neurofibromatosis 2 is a dominantly inherited tumor predisposition syndrome caused by mutations in the NF2 gene on chromosome 22.
  • Meningiomas and ependymomas are other tumor features.
  • In excess of 50% of patients represent new mutations and as many as one third are mosaic for the underlying disease causing mutation.
  • Although truncating mutations (nonsense and frameshifts) are the most frequent germline event and cause the most severe disease, single and multiple exon deletions are common.
  • A strategy for detection of the latter is vital for a sensitive analysis.
  • Surgery remains the focus of current management, although watchful waiting and occasionally radiation treatment have a role.
  • In the future, the development of tailored drug therapies aimed at the genetic level are likely to provide huge improvements for this devastating, life limiting condition.
  • [MeSH-major] Genes, Neurofibromatosis 2. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / genetics
  • [MeSH-minor] Diagnosis, Differential. Genetic Counseling. Genetic Testing. Humans. Prenatal Diagnosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652604.001).
  • [ISSN] 1530-0366
  • [Journal-full-title] Genetics in medicine : official journal of the American College of Medical Genetics
  • [ISO-abbreviation] Genet. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


68. Kinoshita M, Goto T, Okita Y, Kagawa N, Kishima H, Hashimoto N, Yoshimine T: Diffusion tensor-based tumor infiltration index cannot discriminate vasogenic edema from tumor-infiltrated edema. J Neurooncol; 2010 Feb;96(3):409-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion tensor-based tumor infiltration index cannot discriminate vasogenic edema from tumor-infiltrated edema.
  • Diffusion tensor imaging (DTI) by magnetic resonance imaging (MRI) is now used not only for delineating white matter fiber tracts, but also for assessing the histological characteristics of pathological tissues.
  • Among these uses, predicting the extent or existence of tumor cell invasion into white matter by DTI is under extensive investigation.
  • The previously reported tumor infiltration index (TII) holds great potential for the discrimination of pure vasogenic edema from tumor-infiltrated edema.
  • The present investigation reevaluated the utility of TII in patients with meningioma or glioma.
  • We found that TII was unable to discriminate vasogenic from tumor-infiltrated edema.
  • Conversely, detailed voxel-by-voxel comparison of TII and (11)C-methionie PET in the T2-hyperintense area of gliomas showed that TII and (11)C-methionie PET has a positive correlation, suggesting that, although TII is unable to discriminate the cause of edema, the extent of tumor cell invasion into white matter is depicted in gliomas by TII.
  • These data suggest that TII involves both vasogenic and tumor-infiltrated factors, rather than only a single factor.
  • [MeSH-major] Brain Edema / diagnosis. Brain Neoplasms / diagnosis. Glioma / diagnosis. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Aged. Carbon Isotopes. Diffusion Tensor Imaging. Female. Humans. Image Processing, Computer-Assisted. Male. Methionine. Middle Aged. Positron-Emission Tomography / methods. Statistics as Topic. Young Adult

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7163-70 [15534088.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1293-8 [15299051.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4 Suppl 2):ONS-292-303; discussion ONS-303-4 [16582653.001]
  • [Cites] J Neurosurg. 2005 Apr;102(4):664-72 [15871509.001]
  • [Cites] Neuroimage. 2008 Jan 1;39(1):369-82 [17911032.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 May;24(5):937-41 [12748097.001]
  • [Cites] J Neurooncol. 2003 Jun;63(2):109-16 [12825815.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] Neuroimage. 2005 Apr 1;25(2):424-9 [15784421.001]
  • [Cites] Ann Neurol. 2002 Mar;51(3):377-80 [11891834.001]
  • [Cites] Neuroimage. 2009 Apr 1;45(2):312-8 [19111621.001]
  • [Cites] J Appl Clin Med Phys. 2004 Summer;5(3):66-79 [15753941.001]
  • [Cites] Neuroimage. 2007 Feb 1;34(3):949-56 [17166744.001]
  • [Cites] Neurosurgery. 2005;56(1):130-7; discussion 138 [15617595.001]
  • [Cites] Neuroimage. 2006 May 1;30(4):1219-29 [16364659.001]
  • [Cites] Int J Appl Radiat Isot. 1979 Jul;30(7):393-9 [478664.001]
  • [Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Jun;29(6):1176-82 [18388218.001]
  • [Cites] Neuroimage. 2008 Oct 15;43(1):29-35 [18672074.001]
  • [Cites] Radiology. 2004 Jul;232(1):221-8 [15220505.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):128-33 [17236498.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):682-9 [7674019.001]
  • [Cites] Radiology. 2004 Aug;232(2):451-60 [15215555.001]
  • [Cites] Neuroimage. 2004 Sep;23(1):46-53 [15325351.001]
  • [Cites] Neurosurgery. 2005 Jan;56(1 Suppl):98-109; discussion 98-109 [15799797.001]
  • [Cites] J Magn Reson B. 1994 Mar;103(3):247-54 [8019776.001]
  • [Cites] Magn Reson Med. 2005 Nov;54(5):1216-25 [16200554.001]
  • [Cites] Radiology. 2006 Apr;239(1):217-22 [16484348.001]
  • [Cites] Neuroimage. 2009 Feb 1;44(3):653-60 [18951985.001]
  • [Cites] J Nucl Med. 2007 Sep;48(9):1468-81 [17704239.001]
  • [Cites] Biophys J. 1994 Jan;66(1):259-67 [8130344.001]
  • (PMID = 19696968.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


69. Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K: Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res; 2009 Aug 15;15(16):5032-5039
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
  • PURPOSE: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves.
  • Significant morbidity can result from surgical treatment of these tumors.
  • Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2.
  • The lack of effective treatments for NF2 marks an unmet medical need.
  • RESULTS: Workshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials.
  • Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2.
  • [MeSH-major] Clinical Trials as Topic / methods. Consensus. Health Planning Guidelines. Neurofibromatosis 2 / therapy
  • [MeSH-minor] Animals. Auditory Brain Stem Implants. Cochlear Implants. Drug Evaluation, Preclinical / methods. Drug Evaluation, Preclinical / trends. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Time Factors

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2002 Mar;20(3):475-82 [11836557.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):424-8 [17307835.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):20-30 [16409122.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Med Genet. 2008 Jun;45(6):332-9 [18285426.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] Laryngoscope. 2007 Jun;117(6):1069-72 [17545869.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):501-9 [12407444.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):854-65 [19029950.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):978-86 [10215625.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Otol Neurotol. 2005 Jul;26(4):733-40 [16015177.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):58-68 [18199958.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1063-71 [12066908.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] Neurology. 2002 Dec 10;59(11):1759-65 [12473765.001]
  • [Cites] Am J Otol. 1998 Sep;19(5):638-43 [9752973.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1314-9; discussion 1319-20 [18824998.001]
  • [Cites] Neurology. 2007 Feb 27;68(9):643-7 [17215493.001]
  • [Cites] Br J Cancer. 2007 Sep 3;97(5):577-81 [17726450.001]
  • [Cites] Stat Med. 1999 Aug 15;18(15):1905-42 [10532877.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):893-903 [17548515.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 19671848.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / K08 DC009288
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Number-of-references] 36
  • [Other-IDs] NLM/ NIHMS707923; NLM/ PMC4513640
  •  go-up   go-down


70. Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH: Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor. Bioorg Med Chem Lett; 2009 Aug 15;19(16):4720-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ROS1 protein is a receptor tyrosine kinase that has been reported mainly in meningiomas and astrocytomas, and until now, there is no selective inhibitor for this kinase.
  • The compound 1 can be used as a promising lead for the development of new selective inhibitors for ROS1 kinase, and it may open the way for new selective therapeutics for astrocytomas.
  • [MeSH-minor] Astrocytoma / drug therapy. Drug Design. Humans

  • BindingDB. BindingDB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596575.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Pyrazoles; 0 / Pyrimidines; 3QD5KJZ7ZJ / pyrazole; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / ROS1 protein, human
  •  go-up   go-down


71. Lu S, Ahn D, Johnson G, Law M, Zagzag D, Grossman RI: Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. Radiology; 2004 Jul;232(1):221-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index.
  • MATERIALS AND METHODS: In this study, diffusion-tensor MR imaging was performed preoperatively in 40 patients with intracranial neoplasms, including meningiomas, metastatic lesions, glioblastomas multiforme, and low-grade gliomas.
  • Histograms of mean diffusivity (MD) and fractional anisotropy (FA) were used to analyze both the tumor and the associated T2 signal intensity abnormality.
  • An additional metric, the tumor infiltration index (TII), was evaluated.
  • The TII is a measure of the change in FA presumably caused by tumor cells infiltrating the peritumoral edema.
  • Regarding intraaxial tumors, the measured mean peritumoral MD of metastatic lesions, 0.733 x 10(-3) mm(2)/sec +/- 0.061 (SD), was significantly higher than that of gliomas, 0.587 +/- 0.093 x 10(-3) mm(2)/sec (P <.05).
  • There was also a statistically significant difference between the TIIs of the edema surrounding meningiomas and metastases (mean, 0 +/- 35) and the TIIs of the edema surrounding gliomas (mean, 64 +/- 59) (P <.05).
  • CONCLUSION: Peritumoral diffusion-tensor MR imaging metrics enable the differentiation of solitary intraaxial metastatic brain tumors from gliomas.
  • In addition, the TII enables one to distinguish presumed tumor-infiltrated edema from purely vasogenic edema.
  • [MeSH-major] Brain Edema / diagnosis. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Echo-Planar Imaging. Female. Glioblastoma / complications. Glioblastoma / diagnosis. Humans. Image Processing, Computer-Assisted. Male. Meningeal Neoplasms / complications. Meningeal Neoplasms / diagnosis. Meningioma / complications. Meningioma / diagnosis. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2004
  • (PMID = 15220505.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR 0201
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


72. Benesch M, Siegler N, Hoff Kv, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C: Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs; 2009 Oct;20(9):794-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
  • This retrospective study aimed to evaluate the safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with refractory or recurrent brain tumors.
  • Nineteen heavily pretreated patients (males, n = 14; females, n = 5; median age at diagnosis 8.5 years; range, 1.4-22 years) were given intrathecal liposomal cytarabine on a compassionate use basis for recurrent refractory medulloblastoma (n = 12), mixed germ cell tumor (n = 2), central nervous system primitive neuroectodermal tumors of the pons (n = 1), anaplastic ependymoma (n = 1), anaplastic oligodendroglioma (n = 1), atypical teratoid rhabdoid tumor (n = 1), or rhabdoid papillary meningioma (n = 1).
  • Duration of treatment ranged from (1/2) to 10 months.
  • Eleven patients (57.9%) did not show any side effects, whereas eight patients (42.1%) developed side effects related to either chemical arachnoiditis (n = 4) or neurological progression (n = 2).
  • Less typical treatment-related symptoms (e.g. lethargy, ataxia, and slurred speech) were observed in two patients.
  • Treatment with intrathecal liposomal cytarabine was discontinued twice because of side effects.
  • In conclusion, although intrathecal liposomal cytarabine was generally well tolerated, it should be used cautiously and only with dexamethasone prophylaxis in extensively pretreated patients with recurrent brain tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Neoplasms / drug therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Compassionate Use Trials. Delayed-Action Preparations. Drug Resistance, Neoplasm. Female. Humans. Infant. Injections, Spinal. Liposomes / administration & dosage. Male. Retrospective Studies. Salvage Therapy. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617818.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Delayed-Action Preparations; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


73. Martinez-Trufero J, Alfaro J, Felipo F, Alvarez M, Madani J, Cebollero A: Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma. Anticancer Drugs; 2010 Sep;21(8):795-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.
  • Meningeal hemangiopericytoma is an uncommon and aggressive malignancy that, in contrast to meningiomas, shows a high propensity for local recurrence and the development of late extraneural metastases.
  • The results of chemotherapy in advanced hemangiopericytoma have been disappointing, and they have been particularly poor in cases located in the meninges.
  • We report a case of a heavily pretreated metastatic meningeal hemangiopericytoma in which fourth-line chemotherapy with trabectedin, a marine-derived antineoplastic agent effective in treating advanced soft tissue sarcomas, resulted in clinical benefit.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / therapeutic use. Hemangiopericytoma / drug therapy. Meningeal Neoplasms / drug therapy. Tetrahydroisoquinolines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622667.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  •  go-up   go-down


74. Bhattacharjee M, Bose I, Sarkar P, Banerjee C, Dutta S, Ghosh A, Mukherjee J, Acharya S, Goswami S, Mazumdar A, Chaudhuri S, Chaudhuri S: A sequential scanning of the immune efficiency in astrocytoma (Grade I to Grade Iii), meningioma and secondary glioma patients with and without therapeutic scheduling. Cancer Invest; 2006 Aug-Sep;24(5):502-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A sequential scanning of the immune efficiency in astrocytoma (Grade I to Grade Iii), meningioma and secondary glioma patients with and without therapeutic scheduling.
  • However, data revealing the immune status in glioma patients with sequential therapeutic interventions is missing.
  • Thus, the study aims at evaluating the sequential immune status of glioma bearing patients (Astrocytoma Grade I to Grade III) receiving conventional therapeutic measures.
  • The results were compared with the immune status of metastatic secondary glioma and meningioma patients where there is minimal immune suppression and the effect of therapeutic intervention on the above score.
  • METHODS: Functional immune parameters of peripheral blood lymphocytes were assayed by CD2 receptors enumeration through E-rosetting and lymphocyte cytotoxicity assay and assessing the generation of reactive oxygen species by NBT assay of peripheral blood macrophages in patient groups bearing Astrocytoma (Grade I to Grade III), meningioma and secondary glioma.
  • RESULTS: Patients bearing Astrocytoma (all 3 grades) showed maximum immune suppression as compared to the normal subjects, diseased meningioma controls, and secondary glioma.
  • Therapeutic interventions viz. radiotherapy, surgery and radiotherapy after surgery and chemotherapy could not recover the suppressed activity of the CD2 bearing lymphocytes and that of peripheral blood macrophages.
  • However, therapeutic scheduling could recover the functional activity of the CD8 bearing lymphocytes and the CD56 NK cells from that of tumor bearing patients.
  • CONCLUSION: Astrocytoma and not meningioma is capable of causing immunesuppression.
  • As the tumor progresses from Grade I to Grade III, a linear reduction in the functional efficacy of immunocytes is seen to occur.
  • Radiotherapy, surgery, and chemotherapy also induces an inhibitory effect towards the host immune system.
  • The inhibitory effect of tumor as well as of therapy were mainly directed towards the CD2 bearing lymphocyte population and the peripheral blood macrophage population.
  • [MeSH-major] Astrocytoma / immunology. Central Nervous System Neoplasms / immunology. Glioma / immunology. Immune Tolerance. Meningioma / immunology
  • [MeSH-minor] Antigens, CD2 / analysis. Antineoplastic Agents / adverse effects. Cytotoxicity Tests, Immunologic. Humans. Macrophages / immunology. Neoplasm Invasiveness. Phagocytosis. Radiotherapy / adverse effects. Rosette Formation. T-Lymphocytes, Cytotoxic / immunology

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939959.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD2; 0 / Antineoplastic Agents
  •  go-up   go-down


75. Ammerlaan AC, Houben MP, Tijssen CC, Wesseling P, Hulsebos TJ: Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation. Childs Nerv Syst; 2008 Jul;24(7):855-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation.
  • OBJECTIVE: We report on a patient who developed a meningioma more than two decades after removal at a young age of an atypical teratoid/rhabdoid tumour (AT/RT), which was due to a germline INI1 mutation, and radio- and chemotherapy.
  • MATERIALS AND METHODS: We present genetic evidence that the meningioma is not a recurrence or metastasis of the AT/RT and not due to the INI1 mutation, but is a radiation-induced tumour.
  • CONCLUSION: This is the first case illustrating that improved survival of young patients with an AT/RT after aggressive treatment may be gained at the cost of an increased risk for the development of radiation-induced, non-INI1-related tumours.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / genetics. DNA-Binding Proteins / genetics. Meningioma / secondary. Mutation / genetics. Rhabdoid Tumor / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adult. Genetic Predisposition to Disease. Humans. Loss of Heterozygosity. Male. Polymorphism, Single Nucleotide. Radiotherapy / adverse effects. Radiotherapy / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Apr;66(4):1403-6 [10739763.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):614-20 [10901233.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):199-201 [11161377.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1002-13 [15200115.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):474-9 [18087273.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E9 [16398473.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):279-84 [16261613.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):97-111 [16855864.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Aug;13(4):272-7 [7547635.001]
  • (PMID = 18236049.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2413122
  •  go-up   go-down


76. Panigrahi S, Das M, Stagler D, Konstantini S, Gmori M, Slavin S, Nagler A: Development of secondary anaplastic oligoastrocytoma after matched unrelated bone marrow transplantation in a child with acute myeloid leukemia. Acta Haematol; 2003;109(4):196-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the late complications of conventional myeloablative alloBMT, the occurrence of secondary malignant solid tumors is of major concern.
  • Secondary malignant and benign brain tumors such as astrocytoma, meningioma and glioblastoma have been described in long-term survivors of conventional myeloablative alloBMT.
  • Here we report a case of secondary anaplastic oligoastrocytoma that developed 7 years after matched unrelated alloBMT for relapsing childhood acute myeloid leukemia (AML) with CNS involvement.
  • Although isolated CNS relapse of primary leukemia following alloBMT is not uncommon, it is important to identify and define potential risk factors that may lead to the development of secondary brain tumors in children who received high-dose chemotherapy and irradiation prior to alloBMT presenting with progressive neurological symptoms and to differentiate them from leukemia relapse with CNS involvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Astrocytoma / etiology. Bone Marrow Transplantation. Brain Neoplasms / etiology. Cranial Irradiation / adverse effects. Leukemia, Monocytic, Acute / therapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Parietal Lobe. Transplantation Conditioning / adverse effects. Transplantation, Homologous
  • [MeSH-minor] Asparaginase / administration & dosage. Asparaginase / adverse effects. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Injections, Spinal. Male. Remission Induction. Whole-Body Irradiation / adverse effects


77. Radovanovic I, Dizdarevic K, de Tribolet N, Masic T, Muminagic S: Pineal region tumors--neurosurgical review. Med Arh; 2009;63(3):171-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pineal region tumors--neurosurgical review.
  • The treatment for the pineal region tumors depends on tumor histology.
  • Nowadays, germinomas can be cured by radiotherapy and chemotherapy without surgical resection but the other pineal region tumors should be primary treated by surgery.
  • For benign pineal tumors (pineocytoma, meningioma, mature teratomas, symptomatic pineal cysts, etc.) radical surgical resection can be curative.
  • For malignant tumors radical surgical resection is not an objective.
  • Serum and CSF markers contribute to the diagnosis of pineal parenchymal tumors. b-HCG is mainly positive in choriocarcinomas, embryonal carcinomas and mixed germ cell tumors and AFP is expressed by yolk sac tumors, embryonic carcinomas, immature teratomas and mixed germ cell tumors, b-HCG is usually low in germinomas which are often positive for PLAP on immunohistochemistry.
  • Fifty-one pineal region tumors were surgically treated by senior author (NdT).
  • Only 17 of them were the neoplasms originating from pineal body (pineal tumors).
  • In conclusion it can be stressed that management of pineal tumors requires a multidisciplinary cooperation.
  • With the exception of germinoma where only a biopsy is needed, the role of the surgeons still remains prominent as resection of pineal tumors requires high technical skill and experience as well as precise clinical judgment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088167.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Bosnia and Herzegovina
  • [Number-of-references] 10
  •  go-up   go-down


78. Nagai H, Yamasaki T, Yamamoto Y, Takada D, Miyazaki T, Sugimoto K, Matsumoto Y, Akiyama Y, Moritake K: [Evaluation of brain tumors by simultaneous dual isotope SPECT with 201Tl-chloride and 99mTc-MIBI]. No Shinkei Geka; 2004 Oct;32(10):1029-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of brain tumors by simultaneous dual isotope SPECT with 201Tl-chloride and 99mTc-MIBI].
  • Single photon emission computed tomography (SPECT) is useful for detecting brain tumors.
  • In this study, we evaluated the utility of simultaneous dual SPECT with 201Tl-Chloride (Tl) and 99mTc-MIBI (MIBI) for diagnosis of brain tumors.
  • We evaluated 20 cases, including 2 glioblastomas, 7 anaplastic astrocytomas, 2 oligodendrogliomas, 2 anaplastic ependymomas, 2 medulloblastomas, 2 meningiomas, 1 malignant meningioma, 1 pituitary adenoma, and 1 craniopharyngioma.
  • There were no correlations between tumor volume and T/N ratio for the two (ER-Tl; r = 0.0095, DR-TI; r = 0.0050, ER-MIBI; r = 0.036, DR-MIBI; r = 0.254).
  • We discuss the difference in the mechanism of accumulation of two tracers and the significance of simultaneous dual SPECT using them for the differential diagnosis of pituitary tumors, regrowth of oligodendrogliomas, and multidrug resistance of chemotherapy.
  • Dual SPECT with Tl and MIBI appears to be useful for the diagnosis of brain tumor.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Thallium Radioisotopes
  • [MeSH-minor] Adenoma / radionuclide imaging. Adult. Aged. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pituitary Neoplasms / radionuclide imaging. Thallium. Tomography, Emission-Computed, Single-Photon / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THALLOUS CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15529789.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Thallium Radioisotopes; 7791-12-0 / thallium chloride; 971Z4W1S09 / Technetium Tc 99m Sestamibi; AD84R52XLF / Thallium
  •  go-up   go-down


79. Tropine A, Dellani PD, Glaser M, Bohl J, Plöner T, Vucurevic G, Perneczky A, Stoeter P: Differentiation of fibroblastic meningiomas from other benign subtypes using diffusion tensor imaging. J Magn Reson Imaging; 2007 Apr;25(4):703-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of fibroblastic meningiomas from other benign subtypes using diffusion tensor imaging.
  • PURPOSE: To differentiate fibroblastic meningiomas, usually considered to be of a hard consistency, from other benign subtypes using diffusion tensor imaging (DTI).
  • MATERIALS AND METHODS: From DTI data sets of 30 patients with benign meningiomas, we calculated diffusion tensors and mean diffusivity (MD) and fractional anisotropy (FA) maps as well as barycentric maps representing the geometrical shape of the tensors.
  • Regarding tensor shape, endothelial meningiomas were represented by spherical tensors (80%) corresponding to isotropic diffusion, whereas the fibroblastic meningiomas showed a high percentage (43%) of nonspherical tensors, indicating planar or longitudinal diffusion.
  • The difference was highly significant (F=28.4; p<0.0001) and may be due to the fascicular arrangement of long spindle-shaped tumor cells and the high content of intra- and interfascicular fibers as shown in the histology.
  • In addition, a capsule-like rim of the in-plane diffusion surrounded most meningiomas irrespective of their histological type.
  • CONCLUSION: If these results correlate to the intraoperative findings of meningioma consistency, DTI-based measurement of FA and analysis of the shape of the diffusion tensor is a promising method to differentiate between fibroblastic and other subtypes of benign meningiomas in order to get information about their "hard" or "soft" consistency prior to removal.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Anisotropy. Diagnosis, Differential. Female. Fibroblasts. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Software

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17345634.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Goldstein B, Armstrong CL, John C, Tallent EM: Attention in adult intracranial tumors patients. J Clin Exp Neuropsychol; 2003 Feb;25(1):66-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attention in adult intracranial tumors patients.
  • This study investigated the neuropsychological effects of intracranial tumors on attention, prior to irradiation and chemotherapy.
  • Subjects (n = 55) being treated for low-grade, supratentorial brain tumors were administered tests of attention and working memory.
  • We divided the tumor patients into a "superficial" regional group (e.g., gliomas that infiltrate white matter and meningiomas attached to the cortical surface) and classified them into four brain regions: anterior left side, anterior right side, posterior left side, posterior right side.
  • All groups were compared to deep tumor (DT) patients (e.g., pituitary and pineal tumors) and a demographically normal control (NC) group (n = 63).
  • While the NC group primarily outperformed the brain tumor groups on the neuropsychological measures, there were instances where the individual brain tumor groups demonstrated higher scores than the NC group.
  • Significant differences among the brain tumor groups were only found on Digits Forward.
  • The DT group performed significantly worse than the superficial regional groups and the combined anterior and combined posterior groups on Digits Forward.
  • The DT group was also worse than the combined left hemispheric and right hemispheric groups on Digits Forward.
  • The fact that the DT group performed similarly to the other patient groups on the remaining attention measures suggests that these tumors are associated with especially poor attentional performance.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12607173.001).
  • [ISSN] 1380-3395
  • [Journal-full-title] Journal of clinical and experimental neuropsychology
  • [ISO-abbreviation] J Clin Exp Neuropsychol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA065438; United States / NCI NIH HHS / CA / R01 CA 65438
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


81. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, Vecht C: Meningioma. Crit Rev Oncol Hematol; 2008 Aug;67(2):153-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma.
  • Meningiomas are mostly benign tumours originating from the arachnoid cap cells, represent 13-26% of all intracranial tumours.
  • Five-year survival for typical meningiomas exceeds 80%, but is poorer (5-year survival <60%) in malignant and atypical meningiomas.
  • Complete surgical excision is the standard treatment.
  • Radiotherapy is currently used in the clinical practice in atypical, malignant or recurrent meningioma at a total dose of 45-60Gy.
  • However, the role of adjuvant irradiation is still controversial and has to be compared in a randomised prospective setting with a policy of watchful waiting.
  • Radiosurgery has gained more and more importance in the management of meningiomas, especially in meningiomas that cannot be completely resected as for many skull base meningiomas.
  • Medical therapy for patients with recurrent, progressive and symptomatic disease after repeated surgery, radiosurgery and radiotherapy is investigational.
  • Hormonal therapy with progesterone antagonists has shown modest results, while chemotherapy with hydroxyurea appears moderately active.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342535.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 184
  •  go-up   go-down


82. Peltier J, Fichten A, Lefranc M, Toussaint P, Desenclos C, Pruvot AS, Nicot B, Le Gars D: [Follicular dural lymphoma. Case report]. Neurochirurgie; 2009 Jun;55(3):345-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follicular dural lymphoma. Case report].
  • A case of a meningeal B-cell lymphoma is described.
  • A 48-year-old man presented with an episode of grand mal seizure following a brain injury.
  • An initial diagnosis of extradural hematoma was made based on the results of the cerebral computerized tomography scan.
  • Magnetic resonance images demonstrated an enhanced mass with a dural tail attached to the meningeal layer of the temporal bone, suggesting a meningioma "en plaque".
  • Operative inspection also suggested a meningioma, but histological analysis and electron microscopy revealed a grade IV follicular B-cell lymphoma.
  • The patient underwent chemotherapy and radiotherapy.
  • The clinicopathological features and treatments were discussed.
  • [MeSH-major] Lymphoma, B-Cell / surgery. Lymphoma, Follicular / surgery. Meningeal Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Hematoma / etiology. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19428037.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


83. Chamberlain MC, Tsao-Wei DD, Groshen S: Temozolomide for treatment-resistant recurrent meningioma. Neurology; 2004 Apr 13;62(7):1210-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide for treatment-resistant recurrent meningioma.
  • A prospective Phase II study of temozolomide (TMZ) was conducted in 16 patients with refractory meningioma.
  • All patients had previously been treated with surgery and involved-field radiotherapy; however, no patient had prior chemotherapy.
  • Time to tumor progression ranged from 2.5 to 5.0 months (median 5.0 months); survival ranged from 4 to 9 months (median 7.5 months).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Resistance, Neoplasm. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Neoplasm Recurrence, Local. Salvage Therapy / methods
  • [MeSH-minor] Administration, Oral. Aged. Dexamethasone / therapeutic use. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15079029.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 7S5I7G3JQL / Dexamethasone; 85622-93-1 / temozolomide
  •  go-up   go-down


84. Cimmino A, Giangaspero F, Pennella A, Serio G, De Tomasi A, Colamaria A, Ricco R: [Oncocytic meningioma. Case report]. Pathologica; 2000 Apr;92(2):82-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oncocytic meningioma. Case report].
  • [Transliterated title] Meningioma oncocitario. Descrizione di un caso.
  • Among the histological variants of meningiomas the oncocytic subtype is rarely observed.
  • Up-today, only six cases of oncocytic meningioma are described.
  • This subtype of meningiomas shows an aggressive behavior and recurrences are more frequent.
  • We describe a case of oncocytic meningioma in a 78-years-old woman.
  • The patient had a history of breast cancer diagnosed 9 years before the brain biopsy; bilateral mastectomy and adjuvant chemotherapy was performed.
  • Neoplastic cells were arranged in sheets and nests delimited by thin fibrous septa rich in vessels.
  • The rarity of oncocytic meningiomas is underlined with only six cases described in the world literature.
  • The immunophenotypic profile and the differential diagnosis of the neoplasm is discussed and the concept of oncocytic meningioma as a distinct entity of tumour is emphasized.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Brain Edema / etiology. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Breast Neoplasms. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / secondary. Carcinoma, Medullary. Diagnosis, Differential. Female. Humans. Neoplasms, Second Primary

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10838873.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Kiwerski JE: Surgery and subsequent rehabilitation for cervical spine tumours compressing neural structures. Ortop Traumatol Rehabil; 2008 Nov-Dec;10(6):620-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone malignancies account for merely about 1.5% of all cancers, with a small percentage of these tumours developing in the cervical spine.
  • However, the cervical spine is also the site of benign tumours and neoplasms involving not only bony tissue.
  • The most common cervical spine neoplasms are intradural tumours, usually extramedullary: neurofibromas, meningiomas or gliomas.Indications for surgery depend of the nature and location of the tumour and the consequences of tumour growth.
  • The choice of surgical approach and manner of stabilisation depend primarily on the location of the lesion and the presence of spinal cord compression.Rehabilitation is indicated in all patients, but is particularly important, and at the same time difficult, when the growth of the tumour has resulted in neurological disturbances.
  • Rehabilitation programmes should be designed individually for each patient and should account for the degree of paresis, stage of the underlying malignant disease, survival prognosis, disturbances in the function of other systems, apart from musculoskeletal apparatus, age of the patient, his or her commitment to treatment and other factors.The treatment of malignant neoplasms is usually associated with an unfavourable outcome.
  • However, combination drug treatments, radiation therapy and surgery with subsequent rehabilitation will often prolong survival, ameliorate suffering and improve patients' quality of life.

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19274865.001).
  • [ISSN] 1509-3492
  • [Journal-full-title] Ortopedia, traumatologia, rehabilitacja
  • [ISO-abbreviation] Ortop Traumatol Rehabil
  • [Language] eng; pol
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 16
  •  go-up   go-down


86. Kashimura H, Inoue T, Ogasawara K, Arai H, Otawara Y, Kanbara Y, Ogawa A: Prediction of meningioma consistency using fractional anisotropy value measured by magnetic resonance imaging. J Neurosurg; 2007 Oct;107(4):784-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of meningioma consistency using fractional anisotropy value measured by magnetic resonance imaging.
  • OBJECT: Preoperative planning for meningiomas requires information about tumor consistency as well as location and size.
  • In the present study the authors aimed to determine whether the fractional anisotropy (FA) value calculated on the basis of preoperative magnetic resonance (MR) diffusion tensor (DT) imaging could predict meningioma consistency.
  • METHODS: In 29 patients with intracranial meningiomas, MR DT imaging was performed preoperatively, and the FA values of the tumors were calculated.
  • Tumor consistency was intraoperatively determined as hard or soft, and the histological diagnosis of the tumor was established.
  • RESULTS: Of the 29 tumors, 11 were classified as hard and 18 as soft.
  • The FA values of fibroblastic meningiomas were significantly higher than those of meningothelial meningiomas (p = 0.002).
  • The FA values of hard tumors were significantly higher than those of soft tumors (p = 0.0003).
  • Logistic regression analysis demonstrated that the FA value was a significant independent predictor of tumor consistency (p = 0.007).
  • CONCLUSIONS: The FA value calculated from preoperative MR DT imaging predicts meningioma consistency.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17937223.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Salhia B, Rutka JT, Lingwood C, Nutikka A, Van Furth WR: The treatment of malignant meningioma with verotoxin. Neoplasia; 2002 Jul-Aug;4(4):304-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of malignant meningioma with verotoxin.
  • Malignant meningiomas (MMs) are aggressive intracranial neoplasms with a 75% 5-year recurrence rate.
  • Verotoxin 1 (VT1) is an Escherichia coli toxin, which has recently been shown to have anti-neoplastic action by targeting the globotriosylceramide (Gb(3)) glycolipid on tumor cells and tumor neovasculature.
  • To investigate the potential use of VT1 as a clinical agent for MM, we initially tested 16 meningiomas for Gb(3) expression.
  • Nine of 11 MMs (82%), but only one of five benign meningiomas (20%), were positive for Gb(3).
  • An orthotopic xenograft model was used to test the efficacy of VT1 treatment for MM.
  • We first demonstrated that Gb(3) was highly expressed by the MM cell line, IOMM-Lee, and that this cell line was highly sensitive to VT1 treatment in vitro.
  • A single intratumoral injection of VT1 significantly improved survival in nude mice harboring intracranial tumours (P<.0001).
  • In addition, the tumors of VT1-treated animals displayed increased apoptosis by TUNEL analysis and showed a significant decrease in cell proliferation, as determined by MIB-5 immunostaining.
  • VT1 treatment of MM is effective in our orthotopic xenograft model, and warrants further exploration as a potential treatment for these highly anaplastic and aggressive neoplasms.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Shiga Toxin 1 / therapeutic use
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Division / drug effects. Drug Screening Assays, Antitumor. Female. Humans. Male. Mice. Mice, Nude. Middle Aged. Neovascularization, Pathologic / drug therapy. Trihexosylceramides / analysis. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Oct 8;1455(2-3):375-86 [10571026.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2901-10 [10515895.001]
  • [Cites] Biosci Rep. 1999 Oct;19(5):345-54 [10763802.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):493-505 [10898356.001]
  • [Cites] Brain Res. 2000 Nov 10;883(1):87-97 [11063991.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Steroids. 2000 Oct-Nov;65(10-11):795-800 [11108890.001]
  • [Cites] Neurol India. 2000 Dec;48(4):338-42 [11146597.001]
  • [Cites] J Neurooncol. 2000 Aug;49(1):27-39 [11131984.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):551-4 [11304690.001]
  • [Cites] Microbes Infect. 2001 May;3(6):493-507 [11377211.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):99-106 [11418306.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):891-7 [11442480.001]
  • [Cites] Acta Neuropathol. 2002 Jan;103(1):1-10 [11837741.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Neurosurgery. 1990 Sep;27(3):389-95; discussion 396 [2234331.001]
  • [Cites] Eur J Cancer. 1993;29A(15):2118-25 [8297651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6996-7000 [7624357.001]
  • [Cites] J Pathol. 1996 Apr;178(4):442-6 [8691324.001]
  • [Cites] Trends Microbiol. 1996 Apr;4(4):147-53 [8728608.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2757-67 [9326243.001]
  • [Cites] Oncol Res. 1997;9(10):553-63 [9507533.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(4):333-40 [9689324.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):137-50 [9892096.001]
  • [Cites] Oncol Res. 1999;11(1):33-9 [10451029.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):306-14 [10659019.001]
  • (PMID = 12082546.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Shiga Toxin 1; 0 / Trihexosylceramides; 71965-57-6 / globotriaosylceramide
  • [Other-IDs] NLM/ PMC1531702
  •  go-up   go-down


88. Oyoshi T, Nakayama M, Hirano H, Shimokawa S, Kuratsu J: Intracranial dural metastasis of mediastinal seminoma--case report. Neurol Med Chir (Tokyo); 2000 Aug;40(8):423-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial dural metastasis of mediastinal seminoma--case report.
  • A 24-year-old male presented with a rare intracranial dural metastasis from a mediastinal germ cell tumor infiltrating the superior vena cava, pericardium, ascending aorta, and lung.
  • One year after the radiotherapy, magnetic resonance imaging revealed a right parasagittal tumor mimicking a meningioma.
  • Partial tumor removal was performed.
  • Two cycles of chemotherapy with carboplatin and etoposide were then performed, and the residual tumor almost completely disappeared.
  • The histological diagnosis of both the mediastinal and intracranial tumors was pure seminoma.
  • Sections of metastatic tumor revealed several thick fibrous septa and numerous epithelioid granulomas infiltrated by plasma cells, intermingled between the clusters of tumor cells.
  • Follow up of patients apparently in remission from mediastinal seminoma without evidence of advanced or recurrent disease at other sites is recommended.
  • [MeSH-major] Brain Neoplasms / secondary. Dura Mater. Mediastinal Neoplasms / pathology. Seminoma / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10979266.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


89. Kobayashi H, Ishii N, Murata J, Saito H, Kubota KC, Nagashima K, Iwasaki Y: Cystic meningioangiomatosis. Pediatr Neurosurg; 2006;42(5):320-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 14-year-old boy without any stigmata of neurofibromatosis type 2 presented intractable complex partial and generalized seizures since the age of 12 years.
  • The tumor was located in the leptomeninges and cerebral cortex.
  • The patient underwent surgical treatment because medical treatment with phenytoin and sodium valproate was not sufficient to control the seizures.
  • Histopathology showed specific features of meningioangiomatosis with meningioma-like nodules.
  • [MeSH-major] Angiomatosis / surgery. Brain Diseases / surgery. Cerebral Cortex / surgery. Meninges / surgery
  • [MeSH-minor] Adolescent. Electroencephalography. Humans. Male. Seizures / drug therapy. Seizures / etiology. Seizures / surgery

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16902347.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


90. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, Yasui Y, Kasper CE, Mertens AC, Donaldson SS, Meadows AT, Inskip PD: New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst; 2006 Nov 1;98(21):1528-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Subsequent primary neoplasms of the central nervous system (CNS) have frequently been described as late events following childhood leukemia and brain tumors.
  • However, the details of the dose-response relationships, the expression of excess risk over time, and the modifying effects of other host and treatment factors have not been well defined.
  • Each patient was matched with four control subjects by age, sex, and time since original cancer diagnosis.
  • Tumor site-specific radiation dosimetry was performed, and chemotherapy information was abstracted from medical records.
  • Gliomas (n = 40) occurred a median of 9 years from original diagnosis; for meningiomas (n = 66), it was 17 years.
  • Radiation exposure was associated with increased risk of subsequent glioma (OR = 6.78, 95% CI = 1.54 to 29.7) and meningioma (OR = 9.94, 95% CI = 2.17 to 45.6).
  • The dose response for the excess relative risk was linear (for glioma, slope = 0.33 [95% CI = 0.07 to 1.71] per Gy, and for meningioma, slope = 1.06 [95% CI = 0.21 to 8.15] per Gy).
  • For glioma, the ERR/Gy was highest among children exposed at less than 5 years of age.
  • After adjustment for radiation dose, neither original cancer diagnosis nor chemotherapy was associated with risk.
  • CONCLUSIONS: Exposure to radiation therapy is the most important risk factor for the development of a new CNS tumor in survivors of childhood cancers.
  • The higher risk of subsequent glioma in children irradiated at a very young age may reflect greater susceptibility of the developing brain to radiation.
  • [MeSH-major] Brain / drug effects. Brain Neoplasms / epidemiology. Neoplasms, Second Primary / epidemiology. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Factors. Canada / epidemiology. Case-Control Studies. Central Nervous System Neoplasms / epidemiology. Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Glioma / epidemiology. Humans. Incidence. Logistic Models. Male. Meningioma / epidemiology. Neoplasms / therapy. Odds Ratio. Radiometry. Radiotherapy / adverse effects. Retrospective Studies. Risk Assessment. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Nov 1;98(21):1510-1 [17077348.001]
  • (PMID = 17077355.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / PHS HHS / / U24 55727; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Payen JF, Faillot T, Audibert G, Vergnes MC, Bosson JL, Lestienne B, Bernard C, Bruder N: [Thromboprophylaxis in neurosurgery and head trauma]. Ann Fr Anesth Reanim; 2005 Aug;24(8):921-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of deep vein thrombosis (DVT) is between 20 and 35% using contrast venography, with a rate of symptomatic DVT between 2.3 and 6% in neurosurgery without any prophylaxis.
  • Specific risk factors in neurosurgery are: a motor deficit, a meningioma or malignant tumour, a large tumour, age over 60 years, surgery lasting more than 4 hours, a chemotherapy.
  • A postoperative prophylaxis with a LMWH does not seem to increase the risk of intracranial bleeding (grade C).

  • MedlinePlus Health Information. consumer health - Head Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006086.001).
  • [ISSN] 0750-7658
  • [Journal-full-title] Annales françaises d'anesthèsie et de rèanimation
  • [ISO-abbreviation] Ann Fr Anesth Reanim
  • [Language] fre
  • [Publication-type] English Abstract; Guideline; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 34
  •  go-up   go-down


92. Alexiou GA, Gogou P, Markoula S, Kyritsis AP: Management of meningiomas. Clin Neurol Neurosurg; 2010 Apr;112(3):177-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of meningiomas.
  • The primary treatment of meningiomas is surgery which can be curative if the tumor is completely removed.
  • For parasagittal, lateral sphenoid wing and olfactory groove meningiomas, gross-total resection should be the goal.
  • Tuberculum and diaphragma sella meningiomas can be resected through the subfrontal or the pterional approaches.
  • In meningiomas of the sphenoid wing with osseous involvement or involvement of the cavernous sinus subtotal resection can be achieved via several surgical approaches.
  • Similarly, subtotal resection rather than gross-total resection of meningiomas of the petroclival, parasellar, and posterior fossa regions can preserve neurological function.
  • Stereotactic radiosurgery can be used as an alternative treatment to surgery either as a first-line treatment or at recurrence.
  • Various conventional radiotherapy techniques can be employed for residual tumor post surgery or at recurrence.
  • Chemotherapy has modest activity and is reserved for selected cases.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Humans. Neoplasm Staging. Neurosurgical Procedures / methods. Radiosurgery. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20056312.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 94
  •  go-up   go-down


93. Chang KH, Song CE, Seo JH, Yeo SW: Solitary metastasis of bronchogenic adenocarcinoma to the internal auditory canal: a case report. J Korean Med Sci; 2009 Dec;24(6):1227-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 58-yr-old man who had received 6-cycle of chemotherapy under diagnosis of non-small cell lung carcinoma (T4N2M0) two years ago was referred to our department with vertigo, right-sided facial paralysis and right-sided hearing loss.
  • A provisional diagnosis of vestibular schwannoma or meningioma involving right IAC was made from magnetic resonance imaging.
  • The patient underwent a translabyrinthine removal of the tumor.
  • The patient died 9 months after surgery from extensive brain metastasis despite postoperative radiation therapy.
  • In patients with a previous history of treatment of malignancy elsewhere in the body, the possibility of IAC metastasis must be considered when an IAC lesion is detected.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Feb;126(2):209-14 [10680873.001]
  • [Cites] Neuroradiology. 2001 Jan;43(1):52-7 [11214649.001]
  • [Cites] Arq Neuropsiquiatr. 2002 Sep;60(3-A):639-42 [12244407.001]
  • [Cites] J Laryngol Otol. 1985 Sep;99(9):839-46 [2995524.001]
  • [Cites] Am J Otolaryngol. 2006 May-Jun;27(3):214-6 [16647989.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jan-Feb;14(1):99-106 [8427116.001]
  • [Cites] J Laryngol Otol. 1993 Dec;107(12):1087-98 [8288995.001]
  • [Cites] Acta Otolaryngol. 2004 Dec;124(10):1117-23 [15768802.001]
  • [Cites] J Laryngol Otol. 2005 Dec;119(12):1010-2 [16354372.001]
  • [Cites] Am J Otol. 1989 Jul;10(4):297-300 [2801895.001]
  • (PMID = 19949690.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2775882
  • [Keywords] NOTNLM ; Adenocarcinoma / Internal Auditory Canal / Lung Neoplasms / Neoplasm Metastasis
  •  go-up   go-down


94. Braun B, Lange M, Oeckler R, Mueller MM: Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol; 2004 Jun;68(2):131-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization.
  • The hematopoietic growth factors granulocyte- and granulocyte-macrophage colony stimulating factor (G-CSF and GM-CSF) are nowadays widely used in routine cancer therapies as potent factors to control radiation and chemotherapy induced neutropenia, a side effect that frequently endangers the success of tumor therapies.
  • However, there is little information about the role of G-CSF and GM-CSF for tumor growth or progression.
  • We were interested in the expression and potential role of both factors in human meningiomas, tumors of arachnoidal origin that account for about 20% of all primary intracranial tumors.
  • Therefore, we analyzed immunohistochemically the protein expression of G-CSF, GM-CSF and their respective receptors in 30 meningioma tissues of different malignancy and histopathological type.
  • Both factors and receptors were not expressed in the corresponding normal tissue.
  • In contrast, G-CSF, GM-CSF and their receptors were expressed to a varying degree in human meningiomas.
  • Increasing expression of both factors and receptors correlated significantly with enhanced proliferation in the tumor and thus with higher malignancy.
  • In addition, a strong perivascular expression of G-CSF was associated with a highly vascularized tumor type.
  • Thus, expression of both G-CSF and GM-CSF is associated with the expression of proliferation vascularization, two markers of an increasingly malignant tumor phenotype, suggesting a contribution of both factors to tumor progression.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / metabolism. Granulocyte-Macrophage Colony-Stimulating Factor / metabolism. Meningeal Neoplasms / blood supply. Meningeal Neoplasms / pathology. Meningioma / blood supply. Meningioma / pathology. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1994 Nov;81(5):666-75 [7931612.001]
  • [Cites] Am J Hematol. 1995 Jul;49(3):207-15 [7541602.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] Lymphokine Cytokine Res. 1993 Dec;12(6):477-88 [7510132.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Oncogene. 1993 Feb;8(2):231-6 [8426734.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):853-7 [7509778.001]
  • [Cites] Int J Cancer. 1992 Jul 30;51(6):873-7 [1353485.001]
  • [Cites] Arch Dermatol Res. 1995;287(3-4):231-6 [7598526.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6264-7 [2205378.001]
  • [Cites] J Formos Med Assoc. 1994 Feb;93(2):145-52 [7912586.001]
  • [Cites] Eur J Cancer. 1995;31A(3):302-7 [7540401.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3438-43 [7542171.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9253-7 [3057504.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2471-508 [7964965.001]
  • [Cites] Clin Exp Metastasis. 1996 Sep;14(4):351-7 [8878409.001]
  • [Cites] Cell. 2000 Nov 22;103(5):745-55 [11114331.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2791-808 [1720034.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3139-44 [8319222.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1557-67 [10550313.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):780-9 [10597195.001]
  • [Cites] Acta Neurochir (Wien). 1995;137(3-4):174-81 [8789658.001]
  • [Cites] Surg Neurol. 1986 May;25(5):436-40 [3961659.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Head Neck. 1997 Jul;19(4):351-6 [9213115.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4141-7 [9307305.001]
  • [Cites] J Neurooncol. 1999 Sep;44(2):155-62 [10619499.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2611-4 [9205065.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):493-505 [10898356.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):794-800 [9485037.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):905-6; discussion 907 [7688363.001]
  • [Cites] Cytokines Cell Mol Ther. 1998 Jun;4(2):113-20 [9681250.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):949-62 [9060833.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):19-26 [12125963.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1724-31 [8400229.001]
  • [Cites] Rom J Neurol Psychiatry. 1994 Oct-Dec;32(4):237-51 [7779743.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1413-9 [1372187.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):383-7 [10985899.001]
  • [Cites] Hematol Pathol. 1992;6(3):105-24 [1429340.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):541-5 [8123485.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):803-8 [7540696.001]
  • [Cites] J Clin Invest. 1993 Apr;91(4):1310-3 [7682568.001]
  • [Cites] J Clin Invest. 1991 Mar;87(3):986-95 [1705569.001]
  • [Cites] J Neurooncol. 1993 Sep;17(3):183-90 [8164055.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):845-50 [7688362.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1146-53 [1659742.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):78-84 [9935235.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1065-74 [8133992.001]
  • (PMID = 15218949.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


95. Korshunov A, Cherekaev V, Bekyashev A, Sycheva R: Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region. J Neurooncol; 2007 Jan;81(2):131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region.
  • Meningiomas that arise in the sphenoid region (MSR) often display growth patterns leading to widespread invasion and destruction of the surrounding structures.
  • Conventional cytogenetic studies have failed to reveal aberrations characteristic of invasive meningiomas.
  • Mean number of aberrations detected per tumor was significantly greater for invasive meningiomas-67.4 compared with 40.5 for non-invasive MSR.
  • Additionally, invasive MSR disclosed frequent losses on 1p, 6q, 14q and gains on 15q and 20, which were identified previously as molecular hallmarks of stepwise meningioma progression.
  • Inasmuch as no reliable adjuvant therapy for recurrent meningiomas is available thus far, revealed genomic aberrations can provide a potential targets for drug discovery and therapeutic intervention in a future.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics. Sphenoid Bone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2004;21(1):27-34 [15696966.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Surg Neurol. 2005 Jul;64(1):37-43; discussion 43 [15993178.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):59-63 [14756442.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10 (3):869-80 [14871962.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):88-91 [11520574.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):127-33 [15696974.001]
  • [Cites] Arch Pathol Lab Med. 2002 Sep;126(9):1079-86 [12204057.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1163-73 [15509323.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):256-65 [15009703.001]
  • [Cites] Brief Funct Genomic Proteomic. 2003 Apr;2(1):37-45 [15239942.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):296-305 [11414472.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1583-8 [16273260.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2):303-9 [15098535.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):491-7 [16235682.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):601-7 [11596954.001]
  • [Cites] Acta Neuropathol. 2006 May;111(5):465-74 [16557391.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):742-6; discussion 746-7 [10201298.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] Am J Clin Pathol. 2001 Feb;115(2):213-8 [11211609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Pathol. 2004 Jul;203(3):780-8 [15221937.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):145-53 [11958368.001]
  • [Cites] Neurol Res. 2005 Oct;27(7):747-54 [16197812.001]
  • [Cites] J Oral Pathol Med. 2006 Mar;35(3):136-9 [16454808.001]
  • [Cites] Neuro Oncol. 2004 Oct;6(4):281-9 [15494095.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • (PMID = 16850103.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Johnson M, Toms S: Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol; 2005 Dec;64(12):1029-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?
  • These pathways have been extensively studied in gliomas but only recently analyzed in meningiomas.
  • This article reviews current research on the growth factor receptor-Ras-Raf-1-MEK-1-MAPK, PI3K-Akt/PKB, PLC-gamma1-PKC, phospholipase A2-cyclooxygenase, and TGF-beta receptor-Smad pathways that appear to regulate meningioma growth and inhibit apoptosis.
  • Sites along these receptor/kinase cascades that might be targeted by novel therapies are also discussed.
  • [MeSH-major] Meningeal Neoplasms / physiopathology. Meningioma / physiopathology. Mitosis. Receptors, Growth Factor / metabolism. Signal Transduction
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Cell Division / drug effects. Humans. Medical Oncology / trends


97. Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A: Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol; 2004 Mar-Apr;67(1-2):221-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-resectable slow-growing meningiomas treated by hydroxyurea.
  • PURPOSE: To test the benefit of hydroxyurea in the treatment of recurrent and non-resectable slow-growing meningiomas.
  • METHODS: Twelve patients with regrowing non-malignant meningiomas, were enrolled for a protocol of 2 years with continuous chemotherapy with hydroxyurea, 20 mg/kg/day.
  • Response to treatment was evaluated both clinically and by diagnostic imaging using computed tomography (CT) and 201-Thallium single photon emission CT.
  • Nine patients showed progressive disease, at least by one imaging procedure, with a median time to progression of 13 months (range 4-24).
  • CONCLUSION: In this series hydroxyurea has not shown effectiveness in the treatment of non-resectable slow-growing meningiomas: neither for achieving response, nor for arresting disease progression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Tomography, Emission-Computed, Single-Photon. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurosurg. 1997 May;86(5):845-52 [9126901.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):643-57 [8474655.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • (PMID = 15072471.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


98. Nayak L, Iwamoto FM: Primary brain tumors in the elderly. Curr Neurol Neurosci Rep; 2010 Jul;10(4):252-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary brain tumors in the elderly.
  • The incidence of primary brain tumors is highest in elderly patients, and advanced age often is a negative prognostic factor.
  • Elderly patients with primary brain tumors also present unique challenges, such as the presence of multiple comorbidities and polypharmacy, decreased tolerance to chemotherapy, and an increased risk for radiation-induced neurotoxicity.
  • This review gives an overview of the treatment options for older patients with glioblastoma and other gliomas, primary central nervous system lymphomas (PCNSLs), and meningiomas.
  • Selected elderly glioblastoma patients with good performance status may benefit from aggressive treatment with surgical resection, radiotherapy, and possibly chemotherapy.
  • For older patients with PCNSLs, high-dose methotrexate-based chemotherapy should be the mainstay option; whole-brain radiation therapy should be avoided in chemosensitive tumors because of the high risk of irreversible and progressive neurotoxicity.
  • Meningiomas often may be followed up in elderly patients, as they usually are asymptomatic and have a slow growth rate.
  • Treatment for elderly patients with primary brain tumors should be individualized, and age alone should not preclude the use of more aggressive treatments.
  • [MeSH-major] Brain Neoplasms
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroepidemiology. 2009;33(1):17-22 [19325245.001]
  • [Cites] Cancer. 2003 May 1;97(9):2262-6 [12712481.001]
  • [Cites] J Neurooncol. 2008 May;88(1):97-103 [18250965.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):987-92 [17967509.001]
  • [Cites] J Neurosurg. 2009 Jan;110(1):156-62 [18847342.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1583-8 [